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Abstract 
 
 
  
This study was carried out to investigate the incidence of micro flora 
and detecting specific microorganisms in randomly selected samples of 
pharmaceutical products manufactured locally in Wafrapharma 
Laboratories Ltd. 
Non-sterile pharmaceutical products need not to be sterile but may 
contain low levels of microbial load during use. The pharmaceutical 
products prepared in pharmacies have the potential of contamination 
with different microorganisms, this is in part due to the unhygienic 
environment and also lack of a suitable preservative system. This is not 
the case with preparations manufactured in pharmaceutical factories.  
In this study 21 pharmaceutical items (including: tablets, 
suspensions, syrups, and capsules) were examined. The aerobic viable 
microbial count and specific microorganisms per gram or mL of 
product were determined according to the British Pharmacopoeia, 
(2007) using pour plate method. All the examined samples immediately 
after purchase were found to have viable count of less than 102 cfu/g or 
mL. The objectionable organisms e.g., Staphylococcus aureus, 
Escherichia coli, Pseudomonas aeruginosa, and Salmonella species 
were not found.  
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The study demonstrated the possible quality and quantity of micro 
flora of the factory air that might be incriminated as a source of 
microbial contamination of the medical preparations. A review of the 
microbial identification methods that are available to support 
compendial testing was undertaken to determine the state of the art 
within the pharmaceutical industry. Emphasis was given to the 
preliminary screening of microbial isolates for the cellular morphology, 
staining, and diagnostic biochemical reactions to either characterize the 
micro-organisms or support decisions for using different microbial 
identification schemes and the rapid microbial identifications methods 
that are available. The relative advantages of phenotypic microbial 
identification methods are discussed.  
The bacterial flora isolated from different sites in preparation rooms 
and the peripheral air outlets was virtually the same as that found near 
the air-generating installations, consisting of normal skin bacteria and 
the common laboratory contaminant. No pathogenic bacteria were 
isolated.  
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  ﺍﻟﻤﺴﺘﺨﻠﺹ
    
 ﺍﻟﻌﺩﻴﺩ ﻤﻥ ﺕ ﻤﺴﺎﺤﺔ ﻜﺒﻴﺭﺓ ﻓﻲ ﻭﺴﻁ ﻤﺸﻜﻠﺔ ﺍﻟﺘﻠﻭﺙ ﺍﻟﻤﻴﻜﺭﻭﺒﻲ ﻟﻠﻤﻨﺘﺠﺎﺕ ﺍﻟﺼﻴﺩﻻﻨﻴﻪ ﻗﺩ ﺍﺤﺘﻠ    
 ﺘﻌﺘﺒﺭ ﻀﺭﻭﺭﻴﻪ ﻤﻥ ﺍﺠل ﻀﻤﺎﻥ ﺠﻭﺩﺓ ﺎﺘﺤﻘﻴﻘﺎﺘﻬﻭ ،ﺒﻲﺍﻟﻤﺅﻟﻔﻴﻥ ﻭﺍﻟﻬﻴﺌﺎﺕ ﺍﻟﻌﺎﻤﻠﺔ ﻓﻰ ﺍﻟﻤﺠﺎل ﺍﻟﻁ
  . ﻀﻰ ﻗﺒل ﺍﻥ ﺘﺼل ﺍﻟﻰ ﺍﻟﻤﺴﺘﻬﻠﻜﻴﻥ ﺃﻭ ﺍﻟﻤﺭ ﻟﻬﺫﻩ ﺍﻟﻤﻨﺘﺠﺎﺕﻟﺘﻠﻭﺙ ﺍﺍﻟﻤﻨﺘﺠﺎﺕ ﻭﺘﻘﻠﻴل ﻓﺭﺼﺔ
 ﻋﻥ ﻜﺸﻑﺍﻟﻭ ﻨﻔﺫﺕ ﻟﺘﺤﺭﻱ ﻤﺩﻱ ﺘﻠﻭﺙ ﺍﻟﻤﻨﺘﺠﺎﺕ ﺍﻟﺼﻴﺩﻻﻨﻴﺔ ﺒﺎﻟﻜﺎﺌﻨﺎﺕ ﺍﻟﻤﺠﻬﺭﻴﺔ  ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﻪ
ﻴﻪ ﺌ ﺍﺨﺘﻴﺎﺭﻫﺎ ﻋﺸﻭﺍﺌﻴﺎ  ﻤﻥ ﺍﻟﻤﻨﺘﺠﺎﺕ ﺍﻟﺩﻭﺍ ﻋﻴﻨﺎﺕ ﺘﻡﻪ ﻓﻲﻀﺭﻤ ﻤﺤﺩﺩﺓ ﻤﻥ ﺍﻟﻜﺎﺌﻨﺎﺕ ﺍﻟﻤﺍﻨﻭﺍﻉ
  . ﺍﻟﻤﺤﺩﻭﺩﻩ ﺸﺭﻜﺔ ﻤﻌﺎﻤل ﻭﻓﺭﺍﻓﺎﺭﻤﺎ ﻟﻸﺩﻭﻴﺔﺍﻟﻤﺼﻨﻌﻪ ﻤﺤﻠﻴﺎ ﻓﻲ
( ﺍﻷﺤﻴﺎﺀ ﺍﻟﺩﻗﻴﻘﺔﺨﺎﻟﻴﺔ ﻤﻥ  )ﻻ ﺘﺤﺘﺎﺝ ﺍﻟﻰ ﺍﻥ ﺘﻜﻭﻥ ﻋﻘﻴﻤﻪ  ﻏﻴﺭ ﺍﻟﻤﻌﻘﻤﺔﺍﻟﻤﻨﺘﺠﺎﺕ ﺍﻟﺼﻴﺩﻟﻴﻪ
ﺍﻟﻤﻨﺘﺠﺎﺕ  . ﺃﺜﻨﺎﺀ ﺍﻹﺴﺘﻌﻤﺎلﺍﻟﺤﻤﻭﻟﻪ ﺍﻟﻤﻴﻜﺭﻭﺒﻴﻪ  ﻤﻨﺨﻔﻀﻪ ﻤﻥ ﻭﻟﻜﻥ ﻗﺩ ﺘﺤﺘﻭﻱ ﻋﻠﻰ ﻤﺴﺘﻭﻴﺎﺕ
 ، ﻭﻴﺭﺠﻊ ﻫﺫﺍ ﺍﻷﺤﻴﺎﺀ ﺍﻟﺩﻗﻴﻘﺔﻤﺨﺘﻠﻑ ﺒ ﻟﺩﻴﻬﺎ ﺍﻤﻜﺎﻨﻴﻪ ﻟﻠﺘﻠﻭﺙ ﺍﻟﺼﻴﺩﻟﻴﺎﺕ ﺍﻟﻌﻤﻭﻤﻴﺔ ﻓﻲ  ﺍﻋﺩﺕﺍﻟﺼﻴﺩﻟﻴﻪ
 . ﺍﻟﻤﺎﺩﺓ ﺍﻟﺤﺎﻓﻅﻪ ﻤﻥ ، ﻭﺃﻴﻀﺎ ﻋﺩﻡ ﻭﺠﻭﺩ ﻨﻅﺎﻡ ﻤﻨﺎﺴﺏ(ﻤﻌﻘﻤﺔﻏﻴﺭ )ﺠﺯﺌﻴﺎ ﺍﻟﻰ ﺒﻴﺌﺔ ﻏﻴﺭ ﺼﺤﻴﻪ
  .ﻭﻟﻴﺱ ﻫﺫﺍ ﻫﻭ ﺍﻟﺤﺎل ﺒﺎﻟﻨﺴﺒﺔ ﻟﻠﻤﻨﺘﺠﺎﺕ ﺍﻟﺘﻲ ﻴﺘﻡ ﺘﺼﻨﻴﻌﻬﺎ ﻓﻲ ﻤﺼﺎﻨﻊ ﺍﻷﺩﻭﻴﺔ
، ﺸﺭﺍﺒﺎﺕ ، ﻤﻌﻠﻘﺎﺕ ،ﺃﻗﺭﺍﺹ)ﻴﻪ ﻨ ﺍﻟﺼﻴﺩﻻﻨﺘﺠﺎﺕ ﻤﻥ ﺍﻟﻤ ﻋﻴﻨﺔ 12 ﺘﻡ ﺇﺨﺘﺒﺎﺭ ﻓﻲ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﻪ
 ﻟﻠﻐﺭﺍﻡ  ﺍﻟﻤﻤﺭﻀﺔﺍﻟﻜﺎﺌﻨﺎﺕ ﺍﻟﺩﻗﻴﻘﺔﺎﺭﺇﺨﺘﺒﻭ ﻬﻭﺍﺌﻲﺍﻟ ﺇﺨﺘﺒﺎﺭ ﺍﻹﺤﺼﺎﺀ ﺍﻟﻤﻜﺭﻭﺒﻲﺇﻥ (.ﻭﻜﺒﺴﻭﻻﺕ
ﺒﺎﺴﺘﺨﺩﺍﻡ ( 7002 )ﻟﻠﻌﺎﻡﺍﻟﻭﺍﺤﺩ ﻤﻥ ﺍﻟﻤﻨﺘﺞ ﺃﻭ ﻤﻠﻴﻠﺘﺭ ﻜﺎﻨﺕ ﺘﺘﺤﺩﺩ ﻭﻓﻘﺎ ﻟﺩﺴﺘﻭﺭ ﺍﻻﺩﻭﻴﺔ ﺍﻟﺒﺭﻴﻁﺎﻨﻲ 
 ﺇﺤﺼﺎﺀ ﻤﻴﻜﺭﻭﺒﻲ ﻓﻌﺎل ﻟﺩﻴﻬﺎ  ﺍﻥ ﻭﺠﺩ ﺇﺤﻀﺎﺭﻫﺎﻌﻴﻨﺎﺕ ﻓﻭﺭﺍﻟﺤﺹ ﺠﻤﻴﻊ ﺒﻔ.  ﺼﺏ ﺍﻟﻁﺒﻕﻁﺭﻴﻘﺔ
 ﺍﻟﻜﺎﺌﻨﺎﺕ ﺍﻟﺤﻴﺔ .ﺔ ﺘﺤﺕ ﺍﻹﺨﺘﺒﺎﺭﺘﺭ ﻤﻥ ﺍﻟﻌﻴﻨﻠ ﺨﻠﻴﺔ ﺒﻜﺘﻴﺭﻴﺔ ﻓﻲ ﺍﻟﺠﺭﺍﻡ ﺍﻭ ﺍﻟﻤﻠﻴ001ﺍﻗل ﻤﻥ 
 sanomoduesP ، iloc aihcirehcsE  ،suerua succocolyhpatSﺍﻟﻤﺭﻓﻭﻀﻪ ﻤﺜل  ، 
  .ﺓﺩﻭﻭﺠﻤﺍﻟﺴﺎﻟﻤﻭﻨﻴﻼ ﻟﻡ ﺘﻜﻥ ﺃﻨﻭﺍﻉ  ، ﻭasonigurea
ﺍﻟﺘﻲ ﻗﺩ ﺘﻜﻭﻥ ﻭ ﺤﺩﺩﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻴﻀﺎ ﺍﻟﻤﻴﻜﺭﻭﺒﺎﺕ ﺍﻟﻤﻠﻭﺜﺔ ﻟﺒﻴﺌﺔ ﺍﻟﺘﺼﻨﻴﻊ ﺍﻟﺩﻭﺍﺌﻲ ﻜﻤﻴﺎ ﻭﻨﻭﻋﻴﺎ
ﻭﺠﺭﻯ ﺍﻟﺘﺭﻜﻴﺯ ﻋﻠﻰ ﺍﻟﻔﺭﺯ ﺍﻻﻭﻟﻲ .   ﺍﻟﻁﺒﻴﺔ  ﻟﻠﻤﻨﺘﺠﺎﺕ ﺍﻟﻤﻴﻜﺭﻭﺒﻲ  ﺍﻟﺘﻠﻭﺙﻓﻲ  ﻫﺎﻤﺎﹰﻤﺼﺩﺭﺍﹰ
  ﻭﺩﺭﺍﺴﺔ ﺍﻟﺘﺭﻜﻴﺏ ﺍﻟﺨﻠﻭﻱ ﻭﺍﻟﺸﻜل ﺍﻟﻅﺎﻫﺭﻱ ﻋﻠﻲ ﺍﺴﺎﺱ ﻨﺘﺎﺌﺞ ﺍﻟﻔﺤﻭﺼﺎﺕ ﺍﻟﻤﺠﻬﺭﻴﺔﺎﺕﻠﻤﻴﻜﺭﻭﺒﻟ
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ﺒﺈﺠﺭﺍﺀ ﺍﻹﺨﺘﺒﺎﺭﺍﺕ ﺍﻟﺘﺸﺨﻴﺹ ﺜﻡ ، ﻭﺍﻟﺘﻔﺎﻋﻼﺕ ﺍﻟﺼﺒﻐﻴﺔ ،  ﻟﻠﻌﻴﻨﺎﺕ ﺍﻟﻤﻌﺯﻭﻟﺔﻭﺍﻟﺨﺼﺎﺌﺹ ﺍﻹﺴﺘﻨﺒﺎﺘﻴﺔ
   .ﻴﻪﺌﺍﻟﺒﻴﻭﻜﻴﻤﻴﺎ
 ﻩﻭﺤﺩﻋﺩﺍﺩ ﻭﺍﻟﺍﻹ  ﺠﻤﻴﻊ ﻨﻘﺎﻁ ﺍﻟﺘﺼﻨﻴﻊ ﺒﻤﺎ ﻓﻲ ﺫﻟﻙ ﻏﺭﻑﻥﻤ  ﺍﻟﻤﻌﺯﻭﻟﺔﺍﻟﺒﻜﺘﻴﺭﻴﻪ ﺍﻷﻨﻭﺍﻉ 
 ، ﻬﻭﺍﺌﻴﺔ ﺍﻟﺘﻲ ﻭﺠﺩﺕ ﻗﺭﺏ ﺘﺠﻬﻴﺯﺍﺕ ﺍﻟﺘﻭﻟﻴﺩ ﺍﻟﻟﺘﻠﻙ ﺘﻤﺎﻤﺎ ﻤﺸﺎﺒﻬﻪ ﻜﺎﻨﺕ  ﻤﻨﺎﻓﺫ ﺍﻟﻬﻭﺍﺀﺍﻟﻤﻠﺤﻘﺔ ﻭ
  .ﻴﺘﻡ ﻋﺯﻟﻬﺎ ﻟﻡ ﺔ ﺍﻟﻤﻤﺭﻀﺔ ﺍﻟﺒﻜﺘﺭﻴ،ﺍﻤﺎ ﺍﻷﻨﻭﺍﻉ ﻭﻤﻠﻭﺜﺎﺕ ﺍﻟﺠﻭ ﺍﻟﻁﺒﻴﻌﻴﺔﺠﻠﺩ ﺍﻟﺒﻜﺘﻴﺭﻴﺎ ﺘﺸﻤل ﺍﻟﺘﻲ ﻭ
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Chapter One 
Introduction and Literature Review 
1.1. Introduction 
From microbiological view point there are two types of 
pharmaceutical products available, sterile products, which contain no 
viable microorganism, and non-sterile products that contain viable micro-
organisms. These microorganisms should not damage patient or 
formulation. Pathogenic or potentially pathogenic organisms such as 
Escherichia coli, Pseudomonas species and Staphyllococcus aureus 
should be absent.  
The subject of microbial contamination is considered important to 
study because of the much wide use of raw materials of plant or animal 
origin, used in manufacture of a wide variety of medicinal and cosmetic 
products, which are usually highly susceptible to contamination. Recently, 
microbiological quality of non-sterile pharmaceutical product became an 
important issue because of changes in the expectation of the consuming 
public, change in formulations, manufacturing and marketing of non-
sterile drugs, and the introduction of many new ingredients in these types 
of pharmaceutical preparations (Elamin, 1994). 
Microbial considerations play a key role in the successful 
development of pharmaceutical drug products. During formulation 
development, the potential microbial and endotoxin content of the active 
pharmaceutical ingredients and excipients should be considered. The 
testing used to evaluate the ingredients should comply with United State 
Pharmacopoeia General Tests <61> “Microbial Limit Test” and <82> 
“Bacterial Endotoxins Test” (USP, 2004).Typical USP Or NF grade raw 
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materials are selected for use in the formulation and the possible 
contribution each ingredient would make the product bioburden are 
evaluated. Recently, United States Pharmacopeia (USP) has begun adding 
bacterial endotoxin requirements on the basis of maximum human dosage- 
for monograph ingredients that may be used in sterile products. In some 
cases, the blanket compendial Microbial Limits for the Total Aerobic 
Microbial count not > 1000 cfu \g or mL, and Total Combined Yeast and 
Mould Count not > 100 cfu\g or mL found in the draft USP General 
Chapter <1111> may be too loose for some sterile products (USP, 
2003).The contribution that each individual ingredient may make to the 
presterile filtration bioburden, in terms of its concentration on the 
formulation, must be evaluated to minimize the bacterial challenge to the 
sterilizing filter and the endotoxin content of the product. Information 
about the properties and specifications of pharmaceutical ingredients is 
available in the Handbook of Pharmaceutical Excipients (Kibbe, 2000). 
The problem of microbial contamination of non-sterile 
pharmaceutical products is rapidly becoming a matter of worldwide 
concern (Sykes, 1971 and Baird, et al., 1981). It began to attract the 
attention of those working in the medical field since 1964. The first 
inquiry was carried by the Royal Swedish medical board on the 
microbiological contamination of medicinal preparation; this was followed 
by the exhaustive work by Kallings et al; (1966) in which they reported 
200 cases of Salmonella spp. due to thyroid extract tablets contaminated 
with Salmonella, and 87 eye disorders for which Pseudomonas aeruginosa 
was incriminated. This finding led to the official Swedish recommendation 
in 1966 on “Production hygiene and bacteriological control of 
manufacture of pharmaceuticals”. 
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1.2. Literature Review 
1.2.1. Quality assurance of pharmaceuticals 
In the manufacture of pharmaceuticals, quality assurance represents 
a major consideration, with one aspect of quality that products are not 
contaminated with organisms which might affect their safety, efficacy or 
acceptability to the patient or consumer. 
The National Coordinating Committee on Large Volume Parenterals 
(NCCLVP) was established by the US Pharmacopoeial Convention, Inc., 
and subsequently developed and recommended standards of practice for 
the preparation, labelling and quality assurance of hospital pharmacy 
admixture services (NCCLVP, 1975 and Barker, 1981). 
In 1995, the American Society of Health-System Pharmacists 
(ASHP) conducted a national survey of quality assurance for pharmacy-
prepared, as a follow-up to ASHP QA TAB (Myers CE Needed 1996 and 
Santell, Kamalich, 1995). Results of the survey indicated that few 
pharmacies were adequately equipped with controlled compounding 
environment, which are essential for dispensing sterile preparations. The 
survey also documented that many pharmacists were not performing 
critical quality assurance checks, such as environmental monitoring, end- 
product testing, and process validation (Myers, 1996). 
1.2.2. Sources of microbial contamination 
Effective microbiological control of pharmaceutical products 
requires a through understanding of the potential source of contamination. 
Contaminants encountered in pharmaceutical products may originate 
from: a) Raw materials and Excipients; b) Manufacturing equipment; c) 
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The environment of the production area and the working staff; d) 
Containers and closures as well as final packaging materials; and finally 
e) Contaminants might be introduced during the use of the product.  
1.2.3. Control of microbial contamination during product 
manufacture   
 During product manufacture, microbial contamination is mainly 
controlled by the application of good manufacturing practice (GMP) 
while the maintenance of quality during storage and use is achieved 
largely by the inclusion of preservatives also by product design and by 
product formulation and packaging (Bloomfield, 1982). 
1.2.4. Studies of pharmaceuticals 
 Some of the studies were official or national studies as in Sweden 
and Denmark, whilst others were independent surveys. These 
investigations included cosmetics and toiletries as well as 
pharmaceuticals. In the U.K., two official studies of pharmaceuticals 
were initiated, one by the Public Health Laboratory Service to study 
hospital medicaments, the other by the Pharmaceutical Society of Great 
Britain (PSGB) to study all types of products (Bloomfield, 1982). Having 
established the nature and extent of the problem, the next step was to try 
to control it. Various official bodies had to decide the extent to which 
manufacturers should be asked to limit microbial contamination in their 
products and show the standards that should be applied. Inevitably, it is 
found that the limits applied vary from one country and one situation to 
another. Accepted limits may be in-house limits or, for pharmaceuticals, 
may be applied via the pharmacopoeia or licensing systems.  
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1.2.5. Factors affecting the level microbial contamination in 
pharmaceuticals 
 As far as product formulation is concerned, any number of 
physiochemical factors can affect the fate of microorganisms which enter 
a product; these factors include the conditions of water activity, pH and 
osmotic pressure within the product, the availability of nutrient materials, 
and the product storage temperature (Bloomfield, 1982). 
A number of natural conditions diminish host resistance and are 
particularly relevant to a consideration of infection arising from 
contaminated non-sterile pharmaceuticals. Age; genetic constitution, 
malignancies, diabetes and urinary tract abnormalities are all important 
while therapy with corticosteroids, antineoplastic chemotherapy, 
antimicrobial agents and radiation can facilitate infection. 
The warm and rather humid climatic conditions that prevail in most 
tropical countries would tend to support the survival and growth of many 
micro-organisms. In a situation whereby a nutritionally rich 
pharmaceutical/cosmetic product is severely contaminated, rapid growth 
and multiplication would be expected. This could lead to biodegradation 
of the product and risk of infection to consumers of the product (Bos, 
1989). Product contamination may arise from raw materials or water used 
in formulation or accidentally during use. Studies were carried out from 
1995 to 2001 (Malcolm, 1976; Becks, 1995) to assess the incidence and 
hygiene status of simulate actual-use condition of the products in the 
sense that laboratory prepared sterile cream are frequently used in the 
challenge test (Okeke, 2001). Such studies do not, therefore, realistically 
monitor the true capacity of the cream to suppress accidental in-use 
contamination; a very important consideration for successful preservation. 
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1.2.6. Measure to ensure microbiological quality 
When producing pharmaceutical preparations appropriate measures 
have to be taken in order to ensure their microbiological quality. 
Microbially contaminated products can perish and harm the user when 
applied. A recommendation for the microbial purity of pharmaceutical 
products is given in the European Pharmacopoeia (1997) in Chapter 5.1.4 
“Microbiological Quality of Pharmaceutical Preparations” (Gay M., 
1993; Europäisches Arzneibuch, 1997). Additional documents are the 
guidelines for the “good Manufacturing Practice” of pharmaceutical 
products in the PIC-GMP manual (Pic, 1990) and supplementary 
guidelines (Pic, 1992) for liquid, cream, ointment and other drug 
preparations as well as the guidelines for the good pharmacy practice in 
Europe (ZAEU). Drug acts, pharmacy operating decrees and comparable 
legal norms of central European countries (Bundesgesetz 1983; Gesetz; 
Pharmacopoeia Helvetica, 1997; Verordnung §4; Verordnung §3) 
demand a hygienically faultless condition of the preparation premises and 
controlled preparation processes. 
 Pharmaceutical or hygienic products prepared in pharmacies are 
susceptible to contamination with different micro-organisms.  
The incidence of micro-organisms in these preparations is dictated 
by the quality of raw materials, containers, instruments applied, 
environment and the care and attitude of the personnel involved. In 1971, 
the working party of the pharmaceutical society of Great Britain reported 
the contamination of hospital or community pharmacies prepared 
products (public Health Laboratory Services working party Report, 1971). 
Other investigations showed that application of contaminated topical 
products had been associated with the development of infections (Morse, 
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1967; Parrott, 1982). It is also a practice at the pharmacies to dilute 
commercially available topical preparations by addition of bases like 
Eucerin or paraffin with no preservative adjustment or incorporating 
suitable preservative system. This would negatively affect the 
preservative concentration and consequently its antimicrobial activity 
which could prone the product to further contamination during repeated 
patient use. Nobel and Savin (1966) have also reported the contamination 
of a diluted cream containing chlorocresol. 
1.2.7. Microbiological Testing For non-Sterile Pharmaceuticals 
  Microbiological testing of non-sterile pharmaceuticals has thus far 
been performed only in special cases. However, it has been repeatedly 
shown that microbiological control of such products is necessary (Bean, 
1967; Dony, 1968; Kallings, 1966; Lennington, 1967; Savin, 1967a). 
Until now, regulation concerning the permissible level of non-pathogenic 
micro-organisms in non-sterile drugs exists in only a few countries (e.g. 
Czechoslovakia and Scandinavia). 
Non-sterile pharmaceutical products made in nine hospitals were 
examined for microbial contamination as part of a quality assurance 
programmed by Baird (1985). The incidence of contamination was found 
to vary between hospitals. Usually less than 102 cfu\g or mL were 
recorded, but in some cases contaminants were present in relatively high 
numbers, more than 104 cfu\g or mL. When repeated counts were carried 
out, there was evidence that contaminants were not only surviving, but 
also multiplying in these products. 
 A number of reports of contaminated products, in some cases 
leading to infection, appeared in the 1960s. Before that publications were 
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scanty (Savin, 1967a). Sykes (1971) attributed this to the introduction in 
the 1960s of newer types of medicaments having more susceptible 
formulations and an appreciation of the need for better hygienic control. 
It soon became apparent no route of administration was entirely free of 
danger, as the examples given below in table (1). 
Table (1) Non-sterile products as independent reservoirs of infection 
Preparation Infection Organism 
Thyroid tablets Salmonella muenchen 
Carmine capsules Salmonella cubana 
Pancreatin powder Salmonella agona 
Lignocaine jelly Pseudomonas aeruginosa 
Inhalation medication Klebsiella sp., Serratia sp., Pseudomonas sp. 
Topical anesthetic Burkholderia  cepacia 
Hand cream Klebsiella sp.,Pseudomons aeruginosa 
Detergent Psedomonas aeruginosa 
Talcum powder Clostridium tetani 
Cellulose wadding Pseudomonas aeruginosa 
Antiseptic Pseudomdnas spp., Serratia sp. 
 
1.2.7.1. Microbiological Contamination of Raw Materials 
 Micro-organisms will contaminate formulations from a wide 
variety of sources. All aspects of formulation and manufacture should try 
to minimize contamination. This is critical for sterile products. For non-
sterile products it is a balance between the cost of reducing contamination 
against possible risk to the consumer and product. Source of 
contamination include; raw materials, natural raw materials, semi-
synthetic materials, water; personnel, shed skin, operator clothing; 
equipment and environment. 
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 The type of microbial contaminant which is found in raw materials 
reflects the origin of the material (Underwood, 1983). Salmonella species 
have been isolated from product of animal origin, Clostridia from earthly 
powders such as talk and French chalk, and large population of free living, 
water-borne Gram-negative bacteria were commonly found in aqueous 
products (Tremewan, 1946; Kallings et al., 1966; Sykes, 1969).  
When pharmaceutical preparations intended for local application 
and internal dosage forms have no pharmaceutical requirements with 
respect to sterility, these products are usually prepared under conditions 
which do not guarantee microbiological purity of finished product. 
Accordingly, micro-organisms including pathogenic species may be 
primarily incorporated with the raw materials or during intermediate 
manufacturing or the final stage of packaging (Kivman et al., 1984). 
Micro-organisms from raw materials, especially natural ingredients 
such as wool fat or water, from carelessly cleaned equipment or via 
closures can contaminate preparations. The microbial quality of 
pharmaceuticals is influenced by the environment and quality of raw 
materials used during formulation. Some infectious outbreaks have been 
associated with the use of heavily contaminated raw materials of natural 
origin (Kalling, 1966). The incidence of micro flora in non-sterile 
medicines is generally indicated by the nature of the ingredients (whether 
natural or synthetic), the quality of the vehicle and the care and attitude of 
personnel involved in their handling (Parker, 2000). 
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1.2.7.2. Spoilage of Pharmaceuticals 
A spoiled product is one that has been rendered therapeutically 
inactive or one becoming objectionable (Smart and Spooner, 1972). 
Microbial spoilage of medicinal products is affected by the presence of 
bacteria, yeasts or fungi. The contaminating micro-organisms in the 
presence of the appropriate physical and chemical conditions may 
undergo enormous biochemical activites and may modify the nature of 
the product through their enzyme systems. 
Hydrolysis, oxidation, reduction, dehydration, deamination, 
decarboxylation and dephosphorylation are some of the basic chemical 
modifications that can occur (Wedderburn, 1964; Smart and Spooner, 
1972).These reactions can lead to dramatic change in the formulations 
including decomposition, splitting of emulsion, fermentation, change in 
odour or taste, discoloration, gas formation or change in case of cometic 
products (Smart and Spooner, 1972).   
Flavobacteria are commonly encountered spoilage organism which 
are normally non-pathogenic, but Beeckmans et al., (1958) reported an 
incident of Flavobacter causing meningitis in infants. Olsen (1967) 
pointed out that Flavobacterium meningosepticum although non-
pathogenic to adult even when given intramuscularly, may cause severe 
and usually fatal infections in newborns when applied to body surface. 
Salmonella species have been associated with a number of serious 
outbreaks of diseases caused by contaminated pharmaceutical products 
(Kallings et al., 1966; Lang et al., 1967).   
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 Viable cells excrete enzymes to degrade complex macro-molecules 
into easily assimilable nutrients. For example Amylase, present in many 
bacteria and fungi convert starch to sugar. However, sometimes active 
ingredients may be utilized by invading micro-organisms without visible 
signs of spoilage. For example spores of the mould Mucor may be present 
in dormant form and never produce spoilage or harm to the patients who 
take medicine. In contrast the presence of Salmonella in a medicine, 
although causing little or no visible spoilage, this would represent a 
serious health hazard. Changes may occur during storage of a product 
indetectably contaminated during manufacture (Spooner, 1985). This may 
also happen in use as pharmaceuticals, cosmetics and toiletries are 
subjected to high degree of insult by the purchaser. Organisms are readily 
introduced when half-emptied bottles are kept for long periods. Other 
undesirable practices including dipping fingers into the cosmetic cream, 
spitting into the eye-liner or spilling the bath water into the shampoo. 
Mixed flora, introduced into the product by whatever means, are often 
extremely versatile in their metabolic activities and can adapt to a board 
range of environmental conditions. Pharmaceuticals and beauty products 
are highly processed materials and contain an enormous range of natural 
and synthetic materials. Their susceptibility to microbial attack may result 
in extensive growth of contaminants and lead to devastating chemical and 
physical changes in the product, hydrolysis, oxidation, reduction, 
dehydration, deaminationm, decarboxylation, and dephosphorylation are 
the basic chemical modifications that can occur in pharmaceutical 
ingredients, surfactants, polymers, humectants, fats, oil and sweetings 
(Wedderburn, 1964; Smart and Spooner, 1972). Sometimes, growth of 
species may be sequential, one organism paving the way for another. For 
instance, growth of an aerobic organism such as Pseudomonas may be 
followed by that of anaerobe. This sequence is well known in engineering 
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cutting oils and can cause the oil to become blackened owing to the 
eventual proliferation of sulphate-reducing bacteria (Guyne and Bennet, 
1959). 
 Serious hazards of microbial contamination are encountered where 
there are no visual or detectable signs of deterioration or spoilage, and 
when the micro-organism involved is capable of producing toxic 
materials or harmful metabolites (Barnes, 1970; Perlman and Peruzzotti, 
1970).Micro-organisms can produce catabolic products such as organic 
acids and amines which can be toxic to man, or otherwise these 
metabolites may exhibit pharmacological activity (Perlman and 
Peruzzotti, 1970; Smart and Spooner, 1972).   
 Most raw materials for pharmaceutical products support some form 
of microbial growth, depending on the nutritive properties and moisture 
contents. Hence, dry powder or tablets are capable of undergoing some 
form of microbial spoilage or degradation. The more serious of microbial 
contamination of tablets is where there is no obvious signs of spoilage, 
hence, it is usually advisable to have knowledge of the microbial content 
of all drugs and medicines, whether they are required to be sterile or non-
sterile (Parker, 2000). Manufacturing process for tablets reduce the 
viability of microbial cells significantly, hence microbial growth is rarely 
observed (Parker, 1984). 
1.2.7.3. Microbiological Contamination of Liquid Syrup 
 Microbial contamination of non-sterile pharmaceutical liquid 
products is rapidly becoming a matter of worldwide concern (Syke, 1971; 
Baird, et al., 1981). 
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 Many authors have focused their attention on the microbiological 
examination of pharmaceutical syrup (Lambin et al., 1972; Economou-
Stamatelopoulou and Papavassiliou, 1983). 
Lambin (1972) encountered in the 200 samples of pharmaceutical syrup, 
eight percent of the syrup samples contained less than 102 aerobic 
bacteria per millilitre, and about ninety percent contained less than 102 
anaerobic bacteria per millilitre. The most contaminated syrup samples 
contained aerobic and anaerobic bacteria in the magnitude of a few 
thousands bacteria per millilitre. Economou-Stamatelopoulou and 
Papavassiliou, (1983) examined 50 samples of pharmaceutical syrups for 
bacterial and fungal contamination, 72 percent were absolutely free of 
bacteria, 8 percent contained less than 102 bacteria per millilitre, while 
fourteen percent contained more than 104 bacteria per millilitre, 86 
percent were negative for fungi, 10 percent contained less than 102 fungi 
per millilitre, and 4 percent of samples contained between 102 and 103 
fungi per millilitre. 
 The number and type of contaminating micro-organisms was 
examined in a number of pharmaceutical products manufactured in 
Rhodesia by Somerville, (1981).Viable micro-organisms were recovered 
from 33% of the 666 samples examined, and the most highly 
contaminated group of products were oral preparations.  
1.2.7.4. Microbial Contamination of Suspension and Solid Dosage 
 Ohara and Saito (1985) studied the microbial contamination level 
of lots of pharmaceutical suspensions containing different active 
ingredients, 15.7 percent of the tested products were contaminated with 
about ten micro-organisms per millilitre, and 9.3 percent of products 
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recorded contamination levels of 102 organisms per millilitre, while 5 
percent recorded 104 organisms per millilitre. 
 Waterman et al. (1973) carried out a study to determine the ability 
of solid pharmaceutical dosage forms to carry bacteria. They investigated 
the effect of temperature, relative humidity, size of inoculum and storage 
time on the survival of Staphylococcus aureus on the surface of these 
products. It was concluded that the survival rate of this organism 
decreased upon increase of temperature and storage time. The highest 
frequency of survival was recorded in gelatin capsules. 
 Cosmetic creams were contaminated to varying degrees. 
Straphylococci and other Gram-positive cocci were the most commonly 
encountered micro-organism; Gram-negative isolates were hardly found. 
Fungal contaminants consisted largely of Asp. fumigatus, penicilium and 
microsporium species. Challenge test (re-infection) with Staph. aureus 
revealed the commercial products as having low capacity for suppressing 
bacterial proliferation such as may be encountered during in-use 
contamination (Hugbo et al., 2003). 
 Study on the quality of antacid done earlier (Hoq, 1991; Malik, 
1991) gave a gloomy picture and in this study a comparison was made 
between the present and the previous situation. The microbiological status 
of liquid antacid suspension of 20 pharmaceutical industries was studied 
(Hossain et al., 2004). Aerobic viable microbial count of 27 (75 percent) 
out of 36 samples studied were found to exceed the USP Limit-Viable 
microbial count varied between less than 102 CFU mL and greater than 
106 CFU mL. In 11 (30%) samples of 8 companies the total aerobic 
microbial count was more than 103 CFU ml. None of the samples 
contained E. coli or Salmonella spp. Out of 36 samples 1 (2.5%) of the 2 
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samples of one company having different manufacturing dates contained 
Pseudomonas aeruginosa and both samples (5%) having different 
manufacturing date of another large company contained Staphylococcus 
aureus. No significant correlation between pH deviation and 
contamination by microbes was observed. 
The microbial contaminants level in antacid tablets manufactured 
in India was studied by (Jain and Chauhan, 1978) where ten samples were 
selected so as to represent small, medium and large scale manufacturers. 
The average viable count in the ten products tested was 4.36x105 CFU/g. 
However, the extent of microbial contamination in the small scale 
manufacturers was almost four times that of the large scale manufacturer. 
Graft et al., (1989) studied the effect of compression pressures applied to 
tablets dosage forms upon the microbial content of granules prepared by 
wet granulation. It has been found that reduction in germ count depended 
on the compression pressure. 
The number and type of contaminating micro-organisms were 
examined in a number of pharmaceutical products manufactured in 
Rhodesia (Somerville, 1981). 
 In tropical countries, pharmaceutical preparations are frequently 
stored under uncontrolled conditions and may be dispensed in non-
protective packaging or even without any packaging at all, where the 
average temperature is 31° C and the average relative humidity is 75% 
(Grimm, 1986; Blair and Bloomfield, 1988). Dispensing of tablets and 
capsules from large packs is a common practice in hospital pharmacies, 
clinics, nursing home, patient medicine store, some of these packs take an 
average of 3-4 weeks to dispense, depending on the demands. In some 
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cases they would take up to six weeks for such packages like ferrous salts, 
folic acid and vitamin B complex. 
1.2.7.5. Microbial contamination of Herbal Preparations 
 Traditional herbalists use various herbal preparations to treat 
various types of ailment, including diarrhoea, caught “neonatal fistula”, 
convulsions, skin disease etc. (Sofowora, 1982). Most of these 
preparations are used in the form of decoction (soup or drink made 
usually from ingredients after boiling) or infusion (soaking the plant 
materials and allowing it to stand for varying length of time) (Adeleye, 
2003). Medicinal plant materials normally carry a large number of 
microbes originating from the soil. Micro-organisms of various kinds  
normally adhered to leaves, stem, flowers, seeds, and roots. Additional 
contaminants may also be introduced during harvesting, handling, and 
production of various herbal remedies since no conscious efforts are 
made to decontaminate the herbs other than by washing them (Adeley, 
2005). 
1.2.7.6. Preservation of Solid Dosage Forms 
 Historically, the low water content of oral solid dosage forms had 
led to the assumption that such formulations were not at risk from 
microbial contamination. However, a number of reported infection 
outbreaks associated with tablets and capsules have indicated that this is 
not necessarily the case. It was in 1965 that a report by Kallings et al., 
(1966) to the Swedish Journal board of Health first drew attention to 
serious complication of the microbial quality of non-sterile 
pharmaceuticals. They reported high viable counts in contaminated 
tablets, including coliforms up to millions per gram. 
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 The dry nature of solid oral dosage forms renders them an 
inhospitable environment for microbial proliferation; so it is unlikely that 
organisms introduced during processing will flourish, the major risk is 
rather from the indigenous population of contaminants in raw materials, 
both active drug substances and excipients which may be common to 
many formulations. Schiller et al., (1986) surveyed the microbial 
contamination of some pharmaceutical raw materials and found natural 
products, especially those containing extracts of animal origin, to have 
the highest count, e.g. pancreatin, thyroid. 
 Pedersen, and Ulrich, (1986) examined 226 batches of 84 different 
raw materials. The surveys of microbiological quality of tablets and raw 
materials since 1965 showed that dry products may contain high number 
of bacteria and fungi. Most of identified organisms were not necessarily 
associated with disease. 
 Pharmaceutical preparations including syrups, emulsions, tablets, 
suppositories, powders, ointments, liniments and nasal solutions were 
examined to determine their compliance with microbiological standard 
established by the Italian Pharmacopoeia (Pirisino et al., 1985). Only two 
products out of the 34 products examined did not meet the 
pharmacopoeial standards  
 Nandapurkar et al., (1985) studied the microbial contamination of 
pharmaceutical preparations under use in hospital, 31 tablet preparations 
were subjected to study, 35% of these products were free from 
contamination, whereas 65% were found to be contaminated. 10% of 
contaminated samples showed gross contamination and hence were 
rejected. 
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 Bacteriological quality of some pharmaceutical products purchased 
from open markets, buses and drug stores in Uyo metropolis was studied 
in order to determine the level of contamination of the drugs. The drug 
samples examined were tetracycline capsules, paracetamol tablets, 
ampicillin capsules, chloroquine syrup, chloroquine injections, 
metronidazole tablets and chloramphenicol tablets. The bacterial count 
ranged from 2.3×104 cfu/g to 4.4× 104 cfu/g for the 16 samples of 
Ampicillin, 1.8×104 cfu/g to 1.2×105 cfu/g for the 7 samples of unsealed 
capsules of tetracycline, 2.9×104 cfu/g to 3.8×104 cfu/g for the 15 samples 
of paracetamol, 3.8×104 cfu/g to 2.0×108 cfu/ml for the 23 samples of 
chloroquine injection, tablets and syrup, 1.0×104 cfu/g to 4.8×104 cfu/g 
for 15 samples of metronidazole. The organisms isolated were Bacillus 
subtilis (19.0%), Staphylococcus aureus (25.0%), Aerobactor aerogenes 
(7.0%) and Proteus mirabilis (8.0%). Although the count obtained from 
this work were of low levels, the presence of known pathogenic 
microorganisms such as Staph. aureus and Proteus mirabilis in some 
drugs constitutes a health hazard to the public (Alfred et al., 2004). 
 A research was carried out to investigate the incidence of micro 
flora in tablets dispensed from large container packages used in hospitals 
and community pharmacies, the results showed that all the tablets 
sampled had some form of microbial growth. However, aerobic 
mesophilic bacteria and fungi observed were within standard numerical 
limits. It was additionally observed that ascorbic acid and folic acid 
tablets, particularly from the community pharmacies failed the exclusive 
criteria for Enterobacteria and Staphylococci. Tablets from public 
hospitals in general have lower incidence of exclusive microbial 
contamination, compared with community pharmacies (Akerele and 
Godwin, 2003).  
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 The study of microbial quality of Eucerin-urea ointments prepared 
at different pharmacies in Tehran, at the point of sale and also after two 
weeks storage at room temperature was examined. All the samples 
examined immediately after purchase were found to have total viable 
count of lower than 102 cfu/g. The objectionable organisms e.g. Staph. 
aureus, Candida albicans, Escherichia coli and Pseudomonas aeruginosa 
however, were found in about 77%, 45.5%, 9.1% and 4.5% of the 
samples, respectively. After two weeks storage, contamination levels 
increased such that about 36.4% of samples were found to have the total 
viable counts greater than 102 cfu/g and Staph aureus, Candida albicans, 
Escherichia coli and Salmonella spp. were isolated from 86%, 59%, 
18.2% and 9.1% of the samples respectively. Depicted results show that 
significant microbial contamination of unhygienically produced or poorly 
formulated products in pharmacies can occur and because of lacking a 
suitable preservative system, the microbial population will increase 
during storage which may be harmful to the consumers or patients. 
 It has been reported that the most commonly contaminated 
pharmaceutical products were the antacid mixtures containing 
magnesium trisilicate and that these contaminant may survive for long 
period and even grow in the mixtures (British Working Party report, 
1971). Westwood et al., (1972) Fearnely et al., (1972) and Carrington et 
al., (1980) reported the isolation of 34 different strains of micro-
organisms from preserved magnesium trisilicate mixtures whereas 46 
different strains were isolated from unpreserved mixture. It was found 
that a similar range of micro-organisms was present in raw materials.
 The microbiological quality of 240 samples of oral pharmaceutical 
products was evaluated by Garcia-Arribas et al., (1986) who reported that 
 20
about 30% of the tested samples were contaminated by aerobic bacteria. 
Capsules showed the least degree of contamination. 
1.3. Identification of micro-organisms isolated from the 
pharmaceutical industries 
 Environmental monitoring (EIM) is a program designed to 
demonstrate the control of viable and non-viable particles in sensitive 
areas. These areas include clean-rooms, filling lines, tank rooms, laminar 
flow hoods, isolators and laboratories. Viable monitoring include;viable-
testing for bacteria, yeast and molds. It includes surface monitoring, 
personnel monitoring and air monitoring. Companies will check their 
clean room environments to make sure they met the desired/required 
standards. This is called environmental monitoring (McAteer, 2005).
 Microbial identification plays a central role in the clean room 
control program (Sutton, 2004). The aerobic bacterial growth was 
subjected to further identification using the protocol of Cowan and Steel 
(Cowan et al., 2004). The fungal growth was identified both 
microscopically and through the aid of an Atlas of mycology (Rohde, 
1980). 
The total viable aerobic bacterial count (dry surface plate count 
method) and the total viable count for moulds (dry surface plate count 
method) as well as the absence (or presence) of Escherichia coli and 
Staphylococcus aureus were assessed as earlier reported (Van Doorne, 
1997; Waterman et al., 1973). 
1.3.1. Identification of Bacteria 
 Micro-organisms found in pharmaceutical ingredients, water for 
pharmaceutical use, the manufacturing environment, intermediate and 
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finished products are frequently identified to great detail to assist in 
product investigations. This is especially common if their number 
exceeds alert and/or action level for the material or process environment 
test. Routine monitoring might include characterization by colony 
morphology, cellular morphology (rod, cocci, etc.) gram reaction, and 
key enzyme activities.  This information may be sufficient to confirm that 
the bacteria found in the material are typical for that material or process 
environment or indicative of no change in the level of environmental 
control in an aseptic processing area (Sutton, 2004). Most identification 
schemes still rely on the Gram stain, a differential staining technique 
developed in the late 1800’s by Christian Gram (McClelland, 2001). This 
differential counterstaining technique is very good at distinguishing a real 
difference in the cellular morphology. Unfortunately this method is prone 
to a significant level of operator error, which has encouraged the 
development of alternate method for showing the difference in the cell 
structure (Mason et al., 1998; Powers, 1995). Traditional method of 
identification also considers a variety of phenotypic characteristics. 
 There is no USP chapter that specifically addresses microbial 
identification. However, the need for microbial identification is 
specifically cited in USP general Chapter <61> Microbial limit Tests, 
where it is recommended that micro-organisms demonstrating 
characteristic cellular and colonial morphology on selective and/or 
diagnostic agar media in the absence of specified micro-organisms tests 
be confirmed, if necessary, by other suitable cultural and biochemical 
tests. 
 The proposed Microbial Limit Tests harmonization document 
(PDG <62>, 2003) does not includes this specific test. The Australian 
therapeutic goods administration (TGA) recommends testing for the 
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absence of all Pseudomonas in all topical preparations (Tang, 1998) but 
does not provide specific means for identification. FDA, in their 1993 
Guide to inspections of Microbiological Pharmaceutical Quality Control 
Laboratories, references the FDA Bacteriological Analytical Manual 
(FDA, 2001) for microbial identification techniques in reviewing 
microbial limits test that relies heavily on selective and differential media. 
 USP general Chapter <71> Sterility Tests (harmonized with the BP 
and Ph. Eur. January 1, 2004) allows for invalidation of the test if “after 
determination of the identity of the micro-organism isolated from the test, 
the growth of this species (or these species) may be ascribed 
unequivocally to faults with respect to the material and/or the technique 
used in conducting the sterility test procedure”. The TGA document 
contains similar wording (TGA, 2006) but has gone on record that this 
identification must be performed at the level of DNA (TGA, 1999). FDA 
has also argued that invalidation of sterility of test requires identification 
of micro-organisms at the DNA level in its draft aseptic processing 
guideline (FDA, 2003). 
 The manufacturing area is also a concern for microbial 
identification. USP informational chapter <1116> Microbiological 
Evaluation of Clean Rooms and other Controlled Environments 
recommends that microbial isolates be identified at an appropriate level to 
support the environmental monitoring program. The recent FDA draft 
guidelines document on aseptic processing (FDA, 2003) recommends the 
use of genotype microbial identification methods because of the increased 
accuracy and precision of these methods. 
 There is obviously a great deal of interest of microbial 
identification but there is little guidance about how precisely  to conduct 
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it. Although the draft USP informational chapter <1223> Validation of 
Alternative Microbiological Methods provides some guidance (USP, 
2003), the treatment is not complete. There is very little guidance about 
precisely how to qualify different methods of microbial identification, 
and there are many methods to choose from.  
 The routine identification methods employed in the food, clinical 
and microbiology laboratory continue to be based on the determination  
of the morphology, differential staining, and the physiology of a 
microbial isolate by means of miniaturized and automated substrate 
utilization screening methods to speculate the isolate e.g. APT, Vitek and 
Biolog microbial identification system (Manual of Commercial Methods 
in Clinical Microbiology,2002; Automated Microbial Identification and 
Quantification Technologies for the 2000s; 1996). 
1.3.1.1. Microbial Identification of bacteria by Phenotypic Methods 
 Phenotypic microbial identification methods are successfully 
employed in the routine food, water, clinical and pharmaceutical 
microbiological testing laboratory. An excellent overview of normal and 
automated systems for the detection and identification of micro-
organisms may be found in the 8th edition of the ASM Manual of Clinical 
Microbiology (O’Hara et al., 2003). 
 Phenotypic methods typically incorporate reactions to different 
chemicals or different biochemical markers. The API strip is basically 
pre-packaging of the standard method that required racks of tests tubes 
into convenient bubble-wrap. This method was further refined in the 
Vitek automated system which miniaturized the process (Aldridge et al., 
1977; Odlaug et al., 1982). This system has recently been enhanced to 
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provide greater resolution of micro-organisms (Funke, 2004; Funke, 
2005). A second phenotypic system is offered by Biolog, Inc. The 
fundamental unit in this system is a 96-wells plate that has different 
carbohydrate sources in each well, with a tetrazolium redox dye. If the 
micro-organism is capable of utilizing carbohydrate the well turns dark 
indicating reduction of the dye (Miller, 1991; Klingler et al., 1992). The 
use of cellular fatty acid (FA) composition to identify the genus and 
species has been popular for several years (Abel et al., 1963; Eerola, 
1988). The fatty acids are extracted from the cell cultures and then the 
patterns of fatty acid esters are determined by gas chromatography (Olson 
et al., 1990).  
It should be recognized that expression of the microbial phenotype, 
i.e., cell size and shape, sporulation, cellular composition, antigenicity, 
biochemical activity, sensitivity to antimicrobial agents, etc. frequently 
depend on the media and growth condition (Table 2 ). 
Table (2): Phenotypic characteristics that may be employed in microbial taxonomy 
Categories Characteristics 
Cultural Colony morphology, colony color and size and pigment production 
Morphological Cellular morphology, cell size, flagella type, reserve material, Gram 
reaction and spore, and acid fast staining 
Physiological Oxygen tolerance, pH range, temperature optimum and range, and salinity 
tolerance 
Biochemical Carbon utilization, carbohydrate oxidation or fermentation, and enzyme 
patterns 
Inhibition Bile salt tolerance, antibiotic susceptibility, and dye tolerance 
Serological Agglutination 
Chemotaxonomic Fatty acid profile, microbial toxins and whole cell composition 
 
 There are some new methods under development for the 
pharmaceutical QC lab. These include Fourier-Transform Infrared (FTIR) 
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microscopy (Maquelin et al., 2002) and matrix Assisted Laser Desorption 
Ionization-Time of Flight (MALDI-TOF) mass spectroscopy (Fax, 2006 
and Mazzeo, et al., 2006). However, these have not seen widespread use 
in the QC lab as of yet. 
1.3.1.2. Survey of phenotypic methods 
 Representative phenotypic microbial identification systems that are 
widely used in the pharmaceutical industry are listed in table (3) and (4). 
With the substrate utilization methods, the incubation time may be 
shortened from overnight to 2-4 hours by using higher inoculum level 
(Sutton, 2004). 
Table (3): Representative phenotypic microbial identification methods of the family 
Enterobacteriacae 
Product Manufacturer Method 
Incubation 
time 
API 20 E BioMèrieux, Durham, 
NC 
Substrate utilization and 
biochemical reaction 
Overnight 
BBL Crystal Enteric/ 
nonfermenter 
BD diagnostic, Sparks, 
DE 
As above 4 hours 
GN micro-plate Biolog Diagnostic, 
Hayward, CA 
As above As above 
Vitek GNI plus BioMèrieux, Durham, 
NC 
As above 2 hour and/or 
overnight 
MIDI Sherlock MIDI Newark, DE Fatty acid esters analysis Overnight 
MALDI TOF Mass 
Spectrometry with Microbe-
Lynx Software 
Waters Corp., Milford, 
MA 
Spectral analysis of 
ionized cellular 
components 
3 minutes 
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Table (4): Representative phenotypic microbial identification methods for  Staphylococcus spp. 
and other Gram-positive cocci 
Product Manufacturer Method 
Incubation 
time 
API Staph BioMèrieux, Durham, 
NC 
Substrate utilization and 
biochemical reactions 
Overnight 
BBL Crystal Gram-
positive  ID system 
BD Diagnostic, Sparks, 
DE 
As above 4 hours 
Vitek GPI BioMèrieux, Durham, 
NC 
As above 2-15 hours 
Biolog GP Biolog, Hayward, CA As above Overnight 
MIDI Sherlock MIDI Newark, DE Fatty acid esters analysis Overnight 
 
1.3.1.3. Microbial Identification of Bacteria by Genotypic methods 
 In clinical microbiology genotypic identification methods have 
been successfully applied for the identification of fastidious organisms 
(e.g., Clamydia trachomatis and Neisseria gonorrhoeae). Slow-growing 
organisms (e.g., fungal pathogens and Mycobacterium tuberculosis), 
rapid screening for pathogens (e.g., group A Streptococcus confirmatory 
testing), and unculturable organisms (e.g., the Whipple’s bacillus 
Tropheryma whippleii) (Whelen, 1996). 
 The FDA has recently elevated the use of genotypic identification 
methods with the release of the revised aseptic processing guidance 
document late in 2004 (FDA, 2004). 
 The Riboprinter is fundamentally an automated Southern Blot 
apparatus using labelled “DNA probe from the 16s RNA codon. The 
resulting pattern is then used to identify the unknown micro-organism 
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(Bruce, 1996; Jeffrey et al., 2004). If the initial banding pattern is 
inconclusive, then the restriction endonuclease can be changed to provide 
an extraordinary level of strain discrimination (Brisse et al., 2000). 
Another genotypic identification system on the market is the Microseq 
500 16s rDNA Bacterial sequencing kit which is offered by Applied 
Biosystems. As the name implies, it provides the materials needed to 
sequence the first 500 base pairs of the unknown micro-organisms 16s 
ribosomal RNA codon (Fontana et al., 2005). The technology involves 
amplification of the 16s codon by PCR, followed by automated 
sequencing. 
 A final genotypic method that is being marketed into the QC 
pharmaceutical laboratory is the Bacterial Barcodes System (Healy et al., 
2005). This system is also based on PCR technology, using as a primer a 
sequence homologous to a repetitive sequence in the bacterial genome. 
The amplified sequence is then separated by gel electrophoresis and 
visualized to give the ‘barcode’ specific to that strain. 
 Qualicon markets the BAX system to the food industry that 
contains primer for Salmonella, Listeria or E-coli 0157:H7 (Jimenez, 
2001). This system is useful for determination of the absence of specified 
organism in the product. Other genetic methods have been published in 
the literature, although few are available to pharmaceutical market (Olive, 
1999). 
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1.3.2. Identification of fungi 
1.3.2.1. Microbial Identification of fungi by Phenotypic Method  
 Fungi are classified and identified by their morphological features 
rather than their nutritional and biochemical differences. Fungal 
taxonomy is complicated by the existence of teleomorphs (sexual states) 
and anamorphs (asexual states) for the same fungus that develop at 
different times under different nutritional conditions, leading to dual 
species names (Guarro, 1999). Clinical mycologists as well as 
pharmaceutical microbiologists are most familiar with Deuteromycetes 
(anamorphs) or, to use an older terminology, fungi imperfecti. 
Unfortunately, fungal taxonomy is technically difficult and usually 
limited to mycological specialists. Although classical identification 
methods based on morphology are generally applied to fungal 
identification, carbon utilization and biochemical reaction patterns have 
been successfully used to identify yeast, e.g. API 20C and the Biolog FF 
system. These methods are suitable for the routine microbiological testing 
laboratory. Table (5) presents a number of commercially available 
systems for phenotypic identification for fungi. 
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Table (5): Representative microbial phenotypic identification methods for fungi 
Product Manufacturer Method Incubation time 
API 20c (Yeast) BioMèrieux, Durham, 
NC 
Substrate utilization 
and biochemical 
reaction 
24-48 hours 
YT Microplate (Yeast) Biolog, Hayward, CA As above As above 
Vitek YBC (yeast) BioMèrieux, Durham, 
NC 
As above As above 
Biolog FF system 
(filamentous fungi) 
Biolog, Hayward, CA As above 4-14 days 
Microbial identification 
system (MIS) 
MIDI Newark, DE Fatty acid esters 
analysis 
24 hours to 7 days 
 
1.3.2.2. Microbial Identification of fungi by Genotypic Method 
 rRNA gene sequencing and Ribotyping may also be applied to 
fungal identification. For example, recent studies using microseq-D2 
ribosomal DNA sequencing to identify molds and yeasts found in a 
clinical setting determined that 58 and 93.9% of the molds and yeasts 
respectively, that could be identified with isolates were neither identified 
nor included in the Micoseq or API microbial identification system 
libraries (Hall et al., 2003; Hall et al., 2004). Clearly the fungal microseq 
is inadequate for mould identification. 
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Chapter Two 
Scope and objective of the work 
 The importance of maintaining pharmaceutical entities free from 
bacterial contamination has been recognized for many years, and large 
number of incidence of drug related infections have been documented. 
Therefore the objectives of the present study are:  
1. To investigate the levels of aerobic bacterial and fungal 
contamination. 
2. To isolate the more common micro-organisms from environment, 
equipment, machines, human, and raw materials used in 
pharmaceutical products and identify them. 
3. To establishment reasonable home specifications within the 
requirements of British Pharmacopeia 2007 guidance. 
4. To prepare standard operation procedures (SOPs) for hygiene and 
sanitation at pharmaceutical factories in Sudan.  
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Chapter three 
Materials & methods 
3.1. Materials 
The following materials have been used during the experimental part 
of the research: 
3.1.1.Pharmaceutical products  
Pharmaceutical products were obtained from Wafrapharma 
laboratories-Omdurman-Sudan. 
3.1.2. Raw materials and excipients 
 Raw materials and excipients were from: 
- Horst G.F Valtier (DE) - Germany. 
- Salicylates and chemicals PVT.ltd Hamburg-Germany. 
- Antibioticos -Spain. 
- Pharmaceutical coatings Put.Ltd-India. 
- CHP carbohydrate pirna GMbH &Co. kg in pirna -Germany. 
- Orgochem Ltd. -India. 
- DSM Anti-infectives Ltd. India. 
- Ningxia Qiyuan pharmaceutical Co., Ltd. China. 
3.1.3. Chemicals  
All chemicals were obtained from 
- BDH Chemicals Ltd. Poole England. 
- Ridel-de Haen AG.D.3016seelze Ι. 
- Lab Tech chemicals. 
 32
- Sigma chemical company U.S.A. 
- Scharlau chemie S.A. Barcelona-Spain. 
- S.d. fine-chem Ltd. Mumbai. 
- E. Merck, Darmstadt. Germany. 
- El Nasr pharmaceutical chemical co. Egypt. 
3.1.4. Culture media. 
 All culture media were obtained from 
- Oxoid Ltd., Basingstoke, Hampshire, England. 
- Himedia Laboratories Pvt.Ltd. Mumbai. India. 
- Loba chemie PVT.Ltd. Mumbai-India 
- Merck KGaA Darmstadt-Germany 
- S.d.fine-chem Ltd. Mumbai-India. 
3.1.5. Instruments & apparatus 
The following instruments and equipments were used during the course 
of the work 
- Portable steam stericlave-800. Life 
 MEMS &nanotechnology exchange. U.S.A. 
 Registered design No.175945 
- Isotemp® Oven Fisher 
 Model 501 
- VWK≡1520 incubator Shel-lab Sheldon Manufacturing Inc. 
Cornelius, Oregon. 
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 Model 1520 
 Serial No: 7841520 
- Nüve incubator San.Malz LML.ve Tic.A.s. Ankara. Turkey. 
 Type EN400 
 Serial No: 02.601 
- Nüve water bath San.Malz LML.ve Tic.A.S. Ankara. Turkey. 
 Type SB.401 
 Serial NO: 01.393 
- Shimadzu Balance 
 Shimadzu Corporation. Kyoto, Japan. 
 Max: 4200±1g 
3.2. Methods 
3.2.1. Examination of raw materials and pharmaceutical products 
The methods used in this study aimed at detecting the total viable 
aerobic count and specific micro-organisms (BP, 2007).Proposed 
methods of examination have been made by Kallings, et al., (1966) and 
Doney and Gerad (1968). However, these authors expressed different 
views about the permissible limits and method of examination. 
Various considerations were decisive in choosing the method of 
examination. The method should be relatively simple but enable user to 
obtain accurate and reproducibly quantitative results. As far as possible, 
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generally known and universally obtainable culture media should be used. 
Selective media are used only for the demonstration of special groups of 
pathogens. The method should be as widely applicable as possible and 
suitable not only for finished pharmaceuticals but also for bulk products, 
raw materials, active ingredients, and water for pharmaceutical use. 
3.2.1.1. Sampling plan 
The sampling plan will be dependent on factors such as batch size, 
health hazard associated with unacceptably highly contaminated products, 
the characteristics of the product and that expected level of 
contamination. Unless otherwise prescribed 10 g or 10 mL of the 
substance or preparation to be examined was used.  The sample(s) was 
selected randomly from the bulk material or from the available containers 
of the preparation. 
3.2.1.2. Preparation of sample  
In view of these considerations and for technical reasons the 
pharmaceuticals were divided into two categories: 
i.  Aqueous and water-soluble products tested by the membrane              
filter method. 
ii.  Water-insoluble products homogenized in tween 80 and     
phosphate buffer. Suitable homogenous dilutions may be tested by 
the plate count technique and an enrichment method. 
 Prior to bacteriological study, the inhibitory effects of 
antimicrobial agents used as preservatives were removed by 
dilution of the antacids with buffered sodium chloride peptone 
solution (Rawlins, 1966). 
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3.2.1.3.    Examination of sample 
3.2.1.3.1. Membrane filtration 
The membrane filters were used having a nominal pore size of 
0.45µm and their effectiveness to retain bacteria has been established. 
A suitable amount of the sample (prepared as described above) 
was transferred to each of two membrane filters and filtered immediately. 
Each filter was washed with three quantities each about 100 mL of buffer 
sodium chloride-peptone solution pH 7.0.  One of the membrane filters 
was transferred to surface of Soya Bean Casein Digest (SCD) agar 
(intended primarily for the enumeration of bacteria) and the other to the 
surface of Sabouraud Dextrose (SD) agar with antibiotic (intended 
primarily for the enumeration of fungi).  Two plates for each membrane 
filter were prepared for each medium.  The plate of agar medium for 
bacteria was incubated at 32o C for 18-24 hour, and the plate of agar 
medium for fungi at 25o C for five days. Arithmetic average of the count 
was taken and the number of colony forming unit (CFU) per milliliter 
was calculated. 
3.2.1.3.2. Plate count method 
In the present study, total microbial count was performed by pour 
plate method using Petri dishes of 9cm diameter. 1 mL of the diluted 
sample (prepared as described above) was added to each glass Petri dish 
previously sterilized in hot-air oven.  For each sample plating was done in 
duplicate.  The average value obtained was multiplied by the dilution 
factor to get the total microbial count.  Approximately 15 to 20 mL of 
 36
liquefied Soybean Casein Digest (SCD) agar and Sabouraud dextrose 
(SD) agar with antibiotic were added to each Petri dish at 46o C.  Sample 
with (SCD) agar and (SD) agar were incubated at 32o and 25o C, 
respectively.  Both  media were incubated for five days.  Two Petri dishes 
for each level of dilution were prepared for each medium. 
Samples were diluted 100 and 1000 or more times depending on number 
of colony forming unit (CFU) observed in the plate.  Arithmetic average 
of the counts was taken and the number of colony forming units per 
milliliter was calculated.  
3.2.1.3.3. Determination of Enterobacteriaceae 
It is not the aim to detect only pathogen representatives of this 
family of bacteria, Enterobacteriaceae. In general they are considered as 
indicators of inadequate factory hygiene, provided the starting materials 
are uncontaminated (Mossel, 1958). 
Initially to the test 10g of the product was homogenized in 90 mL 
Lactose monohydrate broth and incubated at 35o C to revive the bacteria 
for about three hours. 1 mL homogenized product was then enriched in 
Enterobacteriaceae enrichment broth (EEB) incubated at 32o C for 24 
hours used by Mossell and others, (Mossell, 1963; Schothorst, 1966). For 
confirmation, subculture on Violet Red Bile (VRB) agar plus 1% glucose 
is used (Mossell, 1962).  Enterobacteriaceae forms purple-red to violet-
red colonies. 
In the case of positive finding, inoculation onto ordinary selective media 
can be performed and an accurate differentiation obtained by using 
biochemical testing and phage typing. 
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Test for the detection of Pseudomonas aeruginosa, Escherichia coli, 
Salmonella spp. and Staphyllococcus aureus were done according to the 
standard procedures (Anonymous, 1998).   
3.2.1.3.4 Determination of Pseudomonas aeruginosa 
             Pseudomonas bacteria can cause difficulty in a nearly germ free 
preparation (Bean, 1967; Kallings, 1966; Savin, 1967a). Owing to their 
resistance to many preservatives and their minimal nutrients 
requirements, these bacteria can often multiply in certain preparations. 
This test is therefore indicating for all susceptible products, or where 
there are other grounds for suspecting their presence. The colonies 
streaked onto certimide agar and Pseudomonas isolation agar (Bühlmann, 
1961). If no growth, the product passes the test, if growth of gram 
negative rods occurs, colonies can be identified where necessary by using 
the oxidase test (Kovacs, 1956), or by other  biochemical methods 
(Bühlmann, 1961) such as oxidation-fermentation test (O-F)  
(Cheesbrough, 2000). 
3.2.1.3.5. Detection of Escherichia coli 
To detect E.coli, colonies from Violet Red Bile (VRB) agar were 
streaked onto differential MacConkey and Eosine Methylene Blue (EMB) 
agar, incubated at 35o C for 18-24 hours. Growth of red, non mucoid 
colonies in MacConkey agar, and growth of metallic green colonies in 
(EMB) agar indicates the possible presence of E.coli. This is confirmed 
by suitable indole production biochemical test (Cheesbrough, 2000). 
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3.2.1.3.6. Detection of Salmonella spp. 
One mL of sample in lactose broth was transfer to 9 mL 
Tetrathionate Bile Brilliant Green (TBBG) broth homogenized and 
incubated at 43o C for 24 hours, after the period of incubation it was 
subcultured in Deoxycholate Citrate (DC) agar, Xylose, Lysine, 
Deoxycholate (XLD) agar and Brilliant Green (BG) agar if there is: 
i. Colorless colonies in deoxycholate citrate agar. 
ii. Red colonies, with or without black centre in XLD agar. 
iii. Transparent, colorless or pink or opaque colonies surrounded by 
pink or red zone in brilliant green agar indicated the presence of 
Salmonella spp. The colonies then subculture on the surface of 
Triple Sugar Ion (TSI) agar in a test tube. In the deep inoculation 
culture a change of color from red to yellow and a formation of gas 
confirmed the presence of Salmonella spp. (BP, 2007).  
3.2.1.3.7. Detection of Staphylococcus aureus 
Sample from lactose broth was streaked in Baired-Parker agar and 
incubated at 35o C for 18-72 hour. The observation will be taken 
according to the growth of black colonies of gram positive cocci, 
surrounded by a clear zone indicate the presence of S.aureus. This is 
confirmed by suitable biochemical test, such as coagulase test 
(Cheesbrough, 2000). 
The identities of isolated bacteria on selected media were 
confirmed by gram staining, colonial appearance and biochemical test 
(United States Pharmacopia 2002). 
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3.2.1.3.8. . Detection of Clostridium perfringens 
10gm of the sample to be examined dissolved in 100 mL buffered 
sodium chloride-Peptone solution pH 7, then diluted to 1:100 and 1:1000 
with the same buffer, the most probable number of bacteria was 
determined in a tubes with small durham tube containing Lactose sulphite 
broth. The sample was mixed then the tubes were covered with sterile 
paraffin and incubated at 43o C for two hours. The tubes showing 
blackening due to iron sulphide and abundant formation of gas in Durham 
tube indicate the presence of C. perfringens. 
In all above the sample pass the test if such colonies are not seen or 
if the confirmatory biochemical tests are negative. 
• Bacillus cereus may be detected by the methods of Mossel and 
others. (Dony, 1968; Mossel, 1965).  
• Yeast may be streaked onto Sabouraud chloramphenicol agar and 
incubated at 25o C for 7 days. Resulting colonies were identified by 
germ tube test and morphological characteristics when examined 
microscopically (Domsch, 1980). The fungal growth was identified 
both microscopically and through atlas of mycology (Rohde and 
Hartmann, 1980). 
3.2.2. Identification of microbial isolate 
Microbial identification plays a central role in the clean room 
control program (Sutton, 2004). The method of identification must be 
wedded to the need. 
 Micro-organisms are present in a variety of milieu in the 
pharmaceutical manufacturing environment; the first step to identification 
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is to isolate a pure colony for analysis. This purification is normally 
accomplished by subculturing one or more times on solid media to ensure 
purity, each time streaking for single colonies. This technique also allows 
full phenotypic expression and growth of sufficient inoculums for the 
identification. 
3.2.2.1. Identification of bacteria 
3.2.2.1.1. Characterization of isolates 
Isolates were characterized using different cultural, microscopic 
and biochemical characteristics. 
3.2.2.1.2. Colony characteristics 
Colony characteristics such as shape, size, chromogenesis, opacity, 
elevation, surface, edge, consistency, emulisifiability and odour were 
determined (Harrigan and Margaret, 1966). 
3.2.2.1.3. Growth characteristics 
Growth characteristics such as amount of growth, surface growth, 
turbidity and deposit (Wilson and Miles, 1964) were recorded. 
3.2.2.1.4. Examination of cultures for motility 
To examine the bacterial motility the hanging drop procedure was 
used (Harrigan and Margaret, 1966). In which the bacterial cells were 
grown for 18-24 hours in broth medium. A drop of culture is suspended 
from a cover slip over the depression in a hollow-ground slide. The slide 
examined without delay under the microscope. 
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3.2.2.1.5. Cell morphology and gram reaction 
The bacterial cells were gram-stained according to the procedure of 
Collins et al., (1995). Gram`s staining method is the most important 
bacterial staining method employed for diagnostic identification of 
various organisms (Cruickshank, et al., 1975) 
 A loopfull of bacterial colony was transferred and mixed with a 
drop of sterilized distilled water onto the centre of glass slide. The 
resulting suspension was spread to obtain a thin film and it was left to 
dry. The bacterial cells were fixed by passing the slide over the Bunsen 
burner flame 5-7 times. The gram staining methods employed include the 
four-steps method: crystal violet (primary stain); iodine (mordant); 
alcohol (decolorizer); safranin (counter stain) or the three steps method in 
which the decolorization and counter-staining step are combined. The 
slide was examined under oil immersion lens of compound microscope. 
The cell morphology (i.e. rods or cocci, single cells or chains or clumps 
or clusters, etc.) and their gram reaction were recorded. 
3.2.2.1.6. Spore staining method (Malachite Green Stain) 
 Spore staining method employed includes a two-step method: 
malachite green (primary stain) and safranin (counter stain). The fixed 
bacterial smear is stained with 0.1g/L aqueous malachite green solution 
for 10 minutes, rinsed, and counter stained with 0.25% aqueous safranin 
solution for 15 second, rinsed and blotted dry. The slide examined under 
oil immersion lens. This procedure stains the spores green, but the rest of 
the bacterial cell is stained red (Bartholomew and Mittwer, 1950). 
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3.2.2.2. Biochemical Reactions  
 Bacteria like all living things utilize chemicals and nutrients as a 
source of energy and as building units for their growth and multiplication. 
This activity is mediated by enzymes, which determine the types of 
substrate utilized and the end products of some of these enzymatic actions 
may be measured, or in other cases the disappearance of certain 
substances from the media can be detected (Seeley and Van Demark, 
1972). 
 A series of biochemical tests have been performed during the 
course of this work, to help in the identification and the differentiation of 
the isolated bacteria. These biochemical tests were mainly based on the 
physiological differences of the bacterial cells manifested in the nutrients 
they are able to utilize and the end products of their metabolic process.    
3.2.2.2.1. Hydrolysis of gelatin 
 This reaction is catalyzed by a proteolytic enzyme produced by 
certain bacterial species. It is useful in the identification of Bacillus 
species. 
A poured-dried plate of gelatin agar (consist of nutrient agar in the 
addition of 0.4%gelatin), sterilized by autoclave for 15 min at 121o C, was 
inoculated by streaking once across the surface and incubated at 32o C for 
2-14 days. After the incubation period the plate was flooded with 8-10 
mL mercuric chloride solution (Smith et al., 1952). Hydrolyzed gelatin 
appears as a clear zone. 
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3.2.2.2.2. Hydrolysis of casein 
 Casein is the principal protein of milk, which gives milk its opaque 
whiteness. Many bacteria can degrade casein through the action of their 
enzymes which are able to hydrolyze this protein into more soluble 
transparent derivatives. This hydrolysis breakdown reaction of protein, 
sometimes called peptonisation, is useful in the identification of some 
types of bacterial species. 
A poured-dried plate of milk agar (nutrient agar with the addition of 10% 
skin milk) sterilized by autoclaving for 20 min at 115o C, was inoculated 
by streaking once across the surface and incubated at 32o C for 2-14 days, 
after incubation the plate was flooded with 5ml 1% hydrochloric acid. 
Clear zones were presumptive evidence of casein hydrolysis (Smith et al., 
1952; Chalmers, 1962). 
3.2.2.2.3. Starch hydrolysis 
   This test is used for detection of enzyme amylase produced by 
certain types of micro-organisms. Since not all bacteria can produce this 
enzyme, the ability to hydrolyze starch has been used to aid in the 
identification of Bacillus species (Seeley and Van Demark, 1972). 
A poured-dried plate of starch agar (nutrient agar with the addition of 1% 
soluble starch) sterilized by autoclave for 15 min at 121o C was inoculated 
with tested organism by streaking once across the surface and incubated 
at 32o C for 2-14 days. Then the plate was flooded with Gram's iodine 
solution. Hydrolysed starch therefore appeared as a clear zone (Harrigan 
and Margaret, 1966). 
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3.2.2.2.4. Indole production 
 Kovac’s method was used to perform this test. In this method a few 
drops of Kovac’s reagent (Hi-media, India) were added to an overnight 
peptone water culture. The development of a rose pink color within five 
minutes indicates indole production (Report, 1958; Cowan et al., 2004; 
Cruickshank et al., 1975 and Collins et al., 1995). 
3.2.2.2.5. Production of hydrogen sulphide 
 Production of hydrogen sulphide was tested using lead acetate 
paper which is prepared in the laboratory by soaking strips of filter paper 
(50×5-10mm) in 50g/l (5% w/v) solution of lead acetate (tri-hydrate), and 
allowed them to dry. 
The micro-organism was inoculated in a test tube containing sterilized 
peptone water; the lead acetate paper strip was inserted in the neck of the 
tube above the medium and stopped well. The inoculated medium was 
incubated at 32o C for 2-7 days and examined daily for a blackening of 
the lower part of the strip (Skerman, 1959). 
3.2.2.2.6. Catalase Test 
 Catalase is an enzyme produced by most bacteria and it catalyses 
the break down of hydrogen peroxide to release free oxygen gas and 
water. 
This test was performed by inserting a small amount of culture which was 
picked with a wooden stick into hydrogen peroxide (3% w/v) held in a 
clean tube. Immediate evolving of air bubbles indicates the presence of 
catalase enzyme (Collee, et al., 1996). 
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3.2.2.2.7. Coagulase Test 
 Coagulase is an enzyme produced by certain bacteria and it causes 
plasma to clot by converting fibrinogen to fibrin. 
In this test the slide method was used in which a colony of tested 
organism was emulsified in a drop of physiological saline (0.58% sodium 
chloride in aqueous solution) in one end of the slide. A drop of human 
plasma was added to the suspension and mixed gently. A coagulase 
positive result is indicated by clumping. The second suspension served as 
a control (Harrigan and Margaret, 1966). 
3.2.2.2.8. Oxidase Test 
 Oxidase is an enzyme which catalyses the transfer of electrons 
between two different moieties. Several bacterial species are capable of 
producing this enzyme, the bacterial cell acting as an electron donor and 
tertamethyl-P-phenylenediamine, redox dye, acting as an electron 
acceptor in this reaction. 
1 mL of 1% of aqueous solution of tertamethyl-P-phenylenediamine 
hydrochloride was poured over the surface of the agar growth of micro-
organism under test in a Petri dish. Oxidase positive colonies developed a 
pink color which becomes successively dark red, purple and black in 10-
30 min (Kovacs, 1956; Steel, 1961 and Cruickshank, et al., 1975). 
3.2.2.2.9. Oxidation-Fermentation (O-F) Test 
 Abilities of the isolates bacteria to utilize carbohydrates with the 
production of acids were tested using Hugh and Leifson’s medium (Hugh 
& Leifson, 1953). In this test, sterile carbohydrate solution (10% solution 
sterilized by membrane filtration) was added aseptically to the sterilised 
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melted basal medium. Two tubes of the medium were inoculated with the 
test micro-organism, the surface of medium in one tube was covered with 
sterile paraffin, and the tubes were incubated at 32o C for 2-14 days. Acid 
production was shown by a change in the color of the medium from blue 
to yellow. Fermentative organisms produce acid in both tubes. Oxidative 
organisms produce acid in the open tube only. 
3.2.2.2.10. Deoxribonuclease (DNAse) Test  
  The test organism was cultured in a medium which contained 
DNA. After overnight incubation, the colonies were tested for DNAse 
production by flooding the plate with a weak hydrochloric acid solution. 
DNAse producing colonies were therefore surrounded by a clear area 
indicating DNA hydrolysis. 
3.2.2.2.11. Hydrolysis of Tween compound 
 A poured dried plate of tween agar was inoculated with the test 
micro-organism by streaking once across the center and incubated at 32o 
C for 1-7 days. Opaque zones surrounding microbial growth are usually 
taken as being indicative of positive lipolytic activity (Sierra, 1957). 
3.2.2.2.12. Urease Test 
 Urease is an enzyme produced by several micro-organisms, and its 
activity is important to differentiating enterobacteria. 
Christensen’s urea agar (Christensens, 1946) was used for this test. The 
basal medium was distributed in a test tube, heat-sterilized and cooled to 
50o C ,sufficient 20% urea solution ,previously sterilized by filtration ,is 
then added to give a final concentration of 1%. The medium was slanted, 
allowed to set. The slants were heavily inoculated with a loopfull of 
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bacterial colonies and incubated for 18-24 hours at 32o C. Urease activity 
is known by ammonia production, from urea solution, detected by color 
change in the pH indicator incorporated in the medium, from yellow to 
pink. (Cheesbrough, 1984; Collee et al., 1996). 
3.2.2.2.13. Voges-Proskauer (V-P) Test 
 This test is occasionally used to assist in differentiation of 
enterobacteria and some species of Bacillus which are able to produce 
acetylmethylcarbinol or its reduction product 2, 3-butyleneglycol as a 
result of carbohydrate fermentation. 
The test organisms were cultured in a glucose phosphate peptone broth 
for 24 hours, a knife-point of creatinine was added to the culture followed 
by 5ml of 40% sodium hydroxide. The development of pink color in the 
medium within 30 min indicates positive reaction (O’Meara, 1931; 
Collins et al., 1995). 
3.2.2.2.14. Methyl Red Test 
 Methyl red test detects the ability of several bacterial species to 
produce acidic substances from glucose fermentation but do not convert it 
into neutral products. 
The medium, glucose phosphate peptone broth (as above) was inoculated 
with the test organisms and incubated for 48 hours at32o C. A few drops 
of methyl red solution were added. Positive tests are indicated by change 
in the color of the medium from yellow (pH 6.2) to bright red color (pH 
4.2) indicating activity of the microorganism. (Seeley and Van Demark, 
1972; Cruickshank et al., 1975; Collins et al., 1995). 
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3.2.2.3. Identification of yeast and mould 
3.2.2.3.1. Morphological characteristics 
 Yeast was identified on the basis of morphological and culture 
characteristics: ascospores, ballistospore production, colonical 
appearance, development of aerial sporing structures, chlamydospores, 
sclerotia, etc. (Lodder and Kreger-Van Rij, 1952). 
3.2.2.3.2. Slide culture for examination of the yeasts 
 A petridish containing a filter paper in the base, on which glass rod 
carrying two clean microscope slides was sterilized. After sterilization, a 
few ml of sterile 20% solution of glycerol was added to the filter paper, a 
molten malt extract agar was added to the surface of the slide to form a 
very thin layer of agar medium. Then the slides were inoculated with the 
yeast to be examined in a series of streaks with a wire loop. The 
inoculated medium was covered with a sterile cover slip, and incubated at 
25o C for up to 7 days. The slide was examined under the microscope 
using lactophenol-picric acid (Harrigan and Margaret, 1966). 
3.2.2.3.3. Examination of molds 
 Johnson’s slide culture method (Johnson, 1946) was used to 
identify molds in which a petridish containing a filter paper, glass rod and 
slide was sterilized. A few drops of sterilized 20% glycerol were added, 
two narrow parallel strips were placed across the width of the slide. 
Centrally between the two strips the fungal inoculum was added on the 
slide and then covered with the coverslip, then a sterile melted agar 
medium (cooled to 55o C) was run between the slide and the coverslip 
until the advancing front of medium reached the inoculum. Lastly the 
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edge of the coverslip over the agar medium was sealed and the fourth side 
of the coverslip was left open. The petridish incubated at 25o C for 7 days 
and the culture was examined microscopically using lactophenol-picric 
acid. 
3.2.2.4. Air sample in a pharmaceutical industries  
A petri dishes containing a sterile growth agar medium are exposed 
(opened) to the environment. Viable microorganisms which settle onto 
the medium surface will grow after the plates were incubated. Plates were 
generally exposed for 30-60 minutes. 
3.2.2.5. Surface samples in a pharmaceutical industries 
A sterile swab was rubbed over the tested surface. Then it was sub 
cultured on the surface of a sterile agar medium, and then it was 
incubated to determine the numbers of microorganisms. 
3.2.2.6. Personnel Monitored in pharmaceutical Industries 
Personnel were monitored for microbial contamination utilizing 
contact plates-(special Petri dishes which contain sterile growth medium 
(Agar), prepared  in a manner that results in the surface of the media 
protruding above the side of the plate-). The contact plates monitored part 
of the body that may interact with the sterile field or product exposure 
areas. These included gloved hands, forearms, shoulders, chest, seat and 
feet. Also samples were taken from personnel through shed skin, 
speaking, coughing and sneezing.  
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Chapter four 
Results and Discussion 
 In this study the samples which were examined were taken from 
Wafrapharma Laboratories Company, and they hold the trade names of 
the company. 
4.1. Contamination and Specific Micro-organisms in Pharmaceutical 
Dosage Forms 
4.1.1. Distribution of Micro-organisms on Raw Materials: 
 The results of microbial examination of raw materials and 
excipents are shown in Table (6) and Table (7). The results showed that 
all of raw material used in the company had no growth of both aerobic 
bacteria and fungi, and the excipents had a growth of aerobic bacteria less 
than 102 and no growth of yeasts and moulds. In all raw materials and 
excipents specific microorganisms (E. coli, S. aureus, P. aeruginosa, 
Salmonella spp., and Clostridum spp.) were absent. 
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Table (6): Level of Aerobic Bacterial Contamination in all Raw Materials and Excipients 
Item Batch number Expiry date 
Probable number of 
bacteria per gram of 
sample 
Probable 
number of yeast 
and moulds  per 
gram of sample 
Paracetamol GRAN DC 96% 0609034 09.2010 Absent Absent 
Ciprofloxacin-HCl CH2322KT06 10.2011 Absent Absent 
Cephalexin monohydrate 1721401 10.2010 Absent Absent 
Tetracycline hydrochloride 060611 6.2008 Absent Absent 
Amoxycillin trihydrate Lb. No 74 11.2010 Absent Absent 
Metronidazole B.P. 2007010101 01.2011 Absent Absent 
Glibenclamide G-040718 03-2012 Absent Absent 
Metronidazole Benzoate MBO/17020087 01.2012 Absent Absent 
Chlorphenaramine maleate BL/SC/C/0306282 02.2011 Absent Absent 
Ammonium chloride 733301R396001 02.2009 Absent Absent 
Cloxacillin sodium 1738000607 07.2010 Absent Absent 
Lactose monohydrate 10329325 03.2010 Fewer than 10 Absent 
Talc powder 5161/06 01.2008 Fewer than 10 Absent 
Microcrystalline cellulose 5610274526 01.2011 Fewer than 10 Absent 
Corn starch A608171 08.2009 Fewer than 10 Absent 
 
Table (7): Qualitative Evaluation of Specific Micro-organism in Raw Materials 
Detection of Results for each quantity of sample 
E. coli Absent 
P. aeruginosa Absent 
Salmonella spp. Absent 
S. aureus Absent 
Colsteridia spp. Absent 
 
 Microbial contamination of raw materials is very variable and its 
effects depend on processing and on the micro-organisms considered. 
 Contamination of cosmetic raw materials was dominated by a 
single population of micro-organisms, either gram-negative bacteria or 
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molds. The feasibility of microbial decontamination by irradiation was 
studied by determining the resistance to gamma radiation of 
contaminating microflora in situ. It was expressed as a dose required for 
the first 90% reduction, D first 90% red. The values in the range 1-2 KGY for 
mold and 0.1-0.6 KGY for Gram-negative bacteria were obtained. This 
relatively high susceptibility to irradiation allowed inactivation factors 
close to 6 to be achieved with doses generally not exceeding 3 KGY, and 
yielding endpoint contamination less than 10/g (KatuŠin-Ražem et al., 
2002). 
  Raw materials and finished products were contaminated with low 
levels of microbial contamination. They were artificially contaminated 
with less than 10 CFU of Escherichia coli, Staphylococcus aureus, 
Pseudomonas aeruginosa and Asprigillus niger. Raw materials showed a 
low level of microbial contamination using PCR assays. Rapid quality 
evaluation of pharmaceutical samples resulted in optimization of product 
manufacturing, quality control, and releases of finished products (Jimenez 
et al., 2001). Both experience and logic show that some raw materials are 
usually contaminated and that some never contain any detectable 
contamination (Russel, 1984).During manufacture, the bulk product may 
become contaminated from raw materials, the manufacturing equipment 
and environment and the manufacturing personnel. When the bulk 
product is filled into final containers, it may be contaminated from filling 
equipment and environment, the container or the personnel involved in 
the filling operation (Kallings et al., 1966). 
 The type of microbial contamination that is found in raw materials 
reflects the origin of the material (Underwood, 1983). Raw materials 
obtained from animal or plant origin are usually heavily contaminated. 
However, it was found that raw materials from plant origin provided less 
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contamination level than those from animal or biological origin (Schiller 
et al., 1968, Garcia-Arribas et al., 1983b). 
4.1.2. Distribution of micro-organisms on pharmaceutical products: 
 In this study microbiological quality of 21 of Wafrapharma 
laboratories products were investigated, it included tablets, capsules, 
syrup and suspension. The results are shown in table (8), (9), (10) and 
table (11). The results of specific micro-organisms were shown in table 
(12) and recorded as present or absent. 
Table (8): Level of Aerobic Contamination in Tablets 
Samples to be examined Batch No. Expiry 
date 
Probable number of 
bacteria per gram of sample 
Probable number of moulds 
per gram of sample 
Wafradol 500 0407004 01.2009 N.F N.F 
Wafrastin 4 1907006 02.2009 N.F N.F 
Wafratrim 480 0307004 02.2009 N.F. N.F. 
Wafrafloxacin 500 2807015 02.2009 N.F. N.F. 
Wafrazole 250 0207008 04.2009 N.F. N.F. 
Waframol 4 3007001 04.2009 N.F. N.F. 
Wafranil 5 1807006 04.2009 N.F. N.F. 
N.F. = not found 
Table (9): Level of Aerobic Contamination in Capsules 
Samples to be examined Batch No. 
Expiry 
date 
Probable number of 
bacteria per gram of sample 
Probable number of moulds 
per gram of sample 
Wafraclox 500 1707009 01.2009 N.F. N.F 
Wafraxil 500 1007004 02.2009 N.F. N.F 
Wafraxil 250 0807007 03.2009 N.F. N.F. 
Wafraxin 500 1307004 01.2009 N.F. N.F. 
Wafraxin 250 1207012 02.2009 N.F. N.F. 
Wafrcycline 250 0507012 02.2009 N.F. N.F. 
N.F. = not found 
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Table (10): Level of Aerobic Contamination in Liquid Syrups 
Samples to be examined Batch No. Expiry date Probable number of 
bacteria per gram of sample 
Probable number of moulds 
per gram of sample 
Wafrastin 2907002 02.2009 N.F N.F 
Wafrped expectorant 2407001 03.2009 N.F N.F 
Wafrazole 2607003 05.2009 N.F. N.F. 
N.F. = not found 
Table (11): Level of Aerobic Contamination in Dry Suspension 
Samples to be examined Batch No. Expiry date Probable number of bacteria 
per gram of sample 
Probable number of moulds 
per gram of sample 
Wafraxil 250 1107004 03.2009 N.F. N.F. 
Wafraxil 125 0907045 02.2009 N.F. N.F. 
Wafraxin 250 1507007 02.2009 N.F. N.F. 
Wafraxin 125 1407011 02.2009 N.F. N.F. 
Wafraclox 250 2007017 03.2009 N.F N.F 
N.F. = not found 
Table (12): Qualitative Evaluation of Specific Micro-organisms in Waphrapharma products 
Product to be examined for specific 
microorganisms 
E. coli P. aeruginosa S. aureus Salmonella spp Clostridia spp 
Wafradol 500 Absent Absent Absent Absent Absent 
Wafrastin 4 Absent Absent Absent Absent Absent 
Wafrazole 250 Absent Absent Absent Absent Absent 
Waframol 4 Absent Absent Absent Absent Absent 
Wafratrim 480 Absent Absent Absent Absent Absent 
Wafranil 5 Absent Absent Absent Absent Absent 
Wafrafloxacin 500 Absent Absent Absent Absent Absent 
Wafraclox 500 Absent Absent Absent Absent Absent 
Wafraxil 500 Absent Absent Absent Absent Absent 
Wafraxil 250 Absent Absent Absent Absent Absent 
Wafraxin 500 Absent Absent Absent Absent Absent 
Wafraxin 250 Absent Absent Absent Absent Absent 
Wafrcycline 250 Absent Absent Absent Absent Absent 
Wafrastin syrup Absent Absent Absent Absent Absent 
Wafrped expectorant Absent Absent Absent Absent Absent 
Wafrazole susp Absent Absent Absent Absent Absent 
Wafraxil 250 Absent Absent Absent Absent Absent 
Wafraxil 125 Absent Absent Absent Absent Absent 
Wafraxin 250 Absent Absent Absent Absent Absent 
Wafraxin 125 Absent Absent Absent Absent Absent 
Wafraclox 250 Absent Absent Absent Absent Absent 
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From the above results the frequent occurrence of non pathogenic and 
pathogenic bacteria, Gram-positive spore-form, and fungi was not 
observed. However it has been reported that aerobic mesophilic bacteria 
and fungi exceeded the standard numerical limits for non-sterile oral 
preparation (WHO, 1998 ; Parker, 2000). 
 On MacConkey`s agar, no bacteria were recovered, indicating the 
absence of Enterobacteriaceae and hence, probable adherence to good 
manufacturing protocol. Although the Enterobacteriaceae group was 
generally absent from Wfrapharma products, the frequent isolation of 
Staph. aureus is of some concern because of the pathogenic potential of 
this organism. 
 A pharmaceutical product with good preservative capacity is one 
that is capable of inhibiting immediate post-production contaminant as 
well as subsequent low inocula of in-use contaminants, and thereby 
maintains acceptable low levels of micro-organisms in the preparation. 
The British working party, (1971) reported that among the tablets 
containing synthetic drugs the viable count was usually less than 102 
bacterial cells per tablet, and often less than 10 bacterial cells per tablet. 
Exceptions were specific brands of Aspirin, Dapson, Sulphadimidine and 
Trinitrin tablets, which were found to contain up to 40×103 bacterial cells 
per tablet. 
 Jain and Chauhan (1978) reported an average of 4.36×103 viable 
bacterial cells/gram in 10 antacid tablets examined. The in-house 
microbiological standards for non-sterile products made in Iran, stipulate 
that the Total Aerobic Viable Count (TAVC) should be less than 102 
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cfu/g or mL of the product and certain indicator micro-organisms 
including Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia 
coli, Salmonella spp and Candida albicans should be absent (Fazeli et al., 
2004). 
 Relationship was observed between microbial contamination and 
pH deviation (Hoq, 1991). Changes in the product pH can occur 
depending on whether acidic or basic microbial metabolites are released 
and modification caused by secondary attack by microbes previously 
inhibited by the product initial pH (Hugo, 1998). For non-sterile 
pharmaceutical the pH range for microbial survival is between pH 3 and 
pH 11, within these pH limits the degree of preservation depends very 
much on the formulation type and nature of the hygienic processing. The 
contamination risk increases as the pH approaches 7 (Corlett and Brown, 
1980). 
 The microbial quality of pharmaceutical products is influenced by 
the environment in which they are manufactured and by the materials 
used in their formulation (Hugo, 1998). Markedly spoiled 
pharmaceuticals can often yield surprisingly low numbers of spoilage 
organism (Hugo, 1983). 
 Depicted results show that the incidence of contamination varied 
between pharmacies. The contaminant gram-positive air-borne bacilli 
might  originate from the pharmacy environment. The normal flora of the 
unhygienic pharmacy staff are the likely source for Staphylococcus 
aureus (Luppens et al., 2002). Gram-negative isolates of Pseudomonas 
aeruginosa and Escherichia coli are usually water-borne and may have 
appeared in the products from the water supplies (Ayliffe et al., 1966 and 
Baird et al., 1977). In drawing up microbiological specifications for 
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rational use  within the service, quality control pharmacists have adapted 
a two-pronged approach which combined both requirement for an 
acceptable total viable count and a requirement for the absence of  
potentially pathogenic organisms. The latter included Pseudomonas 
aeruginosa, aerobic spore bearers, Gram-positive coagulase-negative 
cocci and other gram-negative rods (Baird et al., 1976 and Baird, 1985). 
Water is usually part of the ingredients used in processing of the products. 
Contamination may also arise from raw materials supplied in open 
containers exposed to the air and dust and could be contaminated more 
during reported use (Fazeli et al., 2003).  
 It is often forgotten that micro-organisms need a minimum of 70% 
water in order to reproduce. Thus, multiplication in non-aqueous 
materials is impossible. However, some materials, e.g. oils or sugar 
solution, may contain local pockets of free water where microbial 
proliferation may take place. The decision to examine this type of product 
must consider this factor. 
 Ohara and Saito (1985) reported that 17.5% of 140 lots of oral 
suspension were contaminated with more than 10 organisms per mL, 
9.3% with more than 102 organisms per mL and 5% with more than 104 
organisms per mL. 
 Most of products under test were preserved with methyl-propyl 
paraben, they are a good preservatives, as they possess most of the 
properties of an ideal preservative compound. Unfortunately however, 
they lack broad spectrum of activity since they are more active against 
fungi, and less so against bacteria (Lynn, 1981). Moreover, parabens are 
active at pH between 7 and 9 (Hugo, 1983). Inappropriate use of 
preservatives and formulation of the drug may be responsible for this 
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high microbial count. They also possess fairly high dilution coefficient 
(Lynn, 1981) and hence are not likely to exhibit persistent activity in 
presence of extraneous matter or upon dilution. 
 Most oral liquid medicines are prepared as mixtures, suspensions, 
syrups or emulsions. This often contains ingredients which readily 
support the growth of a variety of microorganisms (Baird, 1981; and 
Kalling et al., 1966). 
 As a result, it is necessary to add anti-microbial preservative in the 
formulation process. Inadequate preservation may lead to the exposure of 
microbes to sub-lethal concentration of preservatives and hence develop 
resistant variants (Gilbert, 1987). However, high concentration may prove 
to be toxic for consumer’s health. Preservative should not be expected to 
sterilize formulations that are heavily contaminated as a result of low 
quality raw materials and poor manufacturing procedures (Hugo, 1983). 
 In this study absence of indicator micro-organisms (Pseudomonas 
aeruginosa, Escherichia coli, Staphylococcus aureus and Salmonella spp) 
is an absolute requirement (Anonymous, 1998; Anonymous, 1980). 
However, the study of samples of antacids of two leading pharmaceutical 
companies were heavily contaminated by microbes and both of the 
samples of one company contained coagulase positive Staphylococcus 
aureus and one of the samples of another company was found to contain 
Pseudomonas aeruginosa. None of the samples were found to contain 
Escherichia coli and Salmonella spp. In other two studies (Hoq et al., 
1991 and Malik et al., 1991) on the qualitative analysis of antacid 
suspensions of Bangladesh, absence of Salmonella spp. were confirmed. 
However, in one of the studies, significant number of the samples 
contained Escherichia coli (12.3%) and Pseudomonas aeruginosa (12%) 
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(Hoq et al., 1991). It appears from all these studies above that among the 
specific pathogenic microorganisms Pseudomonas aeruginosa is more 
common. In a different study a high incidence of Pseudomonas 
aeruginosa in liquid antacids was found (Robinson, 2006).  
 Absence of Escherichia coli and Salmonella spp. in all the studied 
samples indicates that the water used by the company may not be 
contaminated by coliform bacteria. The organisms of these types are 
waterborne and frequently contaminate liquid pharmaceutical product 
(Sykes, 1971). 
 In a report by Okeke and Lamikanro (Becks, 1995), gram-negative 
bacilli were not seen in these studies, but like in their report, Salmonella 
spp. was also not isolated. Such outcomes would tend to imply the 
execution of reasonably good manufacturing protocol, but then the initial 
bacterial loads per gram of material exceeded 1.103 which is the 
acceptable bottom line for bacteria in non-sterile topical products (B.P. 
2007). 
 Spoilage of medicine involved basically, initial or early pioneer 
invaders of biodegrading micro-organisms, which prepare the way for 
later invaders, by degrading complex nutrients, altering the surrounding 
pH and making more moisture available (Paker, 1984). At the moment of 
administration of non-sterile pharmaceutical dosage forms like tablets, 
spoilage is dependent on the bioburden of the raw materials, both active 
drug and excipents (Devleeschovwer, 1979 and Khante, 1979). Hence the 
desirability of strictly observing contamination reduction, depends on 
strategy of preventing the proliferation of microbes at every stage of 
production. In an earlier study, aqueous preparations such as magnesium 
trisilicate mixture kaolin and morphine mixture, were found to be highly 
 60
contaminated (Onawunmi, 1999); an observation that has serious health 
implications for the consuming public. Tablets and capsules constitute a 
large proportion of the medicines which are dispensed in modern 
dispensaries. Though many are now presented in blister packs, situations 
in most developing countries like Sudan still present instances where such 
drug are supplied in bulk packs and the prescribed amount counted from 
them. Mishandling of these drugs in the hands of untrained personnel 
could result in serious health hazards following ingestion of highly 
contaminated drugs by patients whose immunity is already compromised 
by illness. It was observed in this study, that most of community 
pharmacies have largely untrained dispensers, hence the dispensing 
benches, spoons, trays are untidily kept. This practice coupled with the 
high level of unhygienic disposition could have explained the high 
incidence of Enterobacteriaceae and Staphylococci species isolated from 
ascorbic acid and folic acid tablets from community pharmacies (Akerele, 
2003). It was also observed that tablets from public hospitals appeared to 
have a lower incidence of microbial contamination, particularly with 
respect to Enterobacteriaceae and Staphylococci species. This could be 
due to less attention to personal hygiene on the part of dispensers in 
community pharmacies, compared with public hospitals. The expected 
higher turnover, and hence less exposure of opened containers, in hospital 
settings, could also explain the lower incidence of Enterobacteriaceae and 
staphylococci species, in public hospitals. It is pertinent to point out that, 
in addition to microbial degradation and spoilage, tablets like aspirin or 
penicillins, could cause life threatening reactions, when allergic persons 
are exposed to very small particles from mishandling. It is for these 
additional reasons that pharmacists must emphasize to dispensers, strict 
observance for accurate tablet counting with devices, properly cleaned, 
before and after use. 
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 Personnel who handle drugs generally and exposed tablets, in 
particular, must wear properly laundered overalls, gloves, facemasks, to 
exclude excessive droplets from nasal passage and buccal cavity, which 
are generally associated with sneezing, coughing or talking. Hand 
washing facilities must in addition be available and usable. Above all, 
more cheaply designed multi-dose packs which dispense tablets 
individually through a shutter release aperture, without having to open the 
container cover would ultimately revolutionize large package dispensing. 
 The study has highlighted the microbial contamination level of one 
of the Sudanese pharmaceutical industries. Strict observance of 
dispensing guidelines would reduce the bioburden of retail dispensing 
and the associated health hazards. 
When a product is tested for the first time, the possibility of 
carryover of the preservative agent should be checked by inoculating 
suitable test organisms on the medium inoculated with the test materials. 
Often colony counts on the higher dilutions must be relied upon for 
accurate counts if the inactivating agent is present in sufficient amount in 
the lower dilution. 
 A preincubation of the test samples is important in foods and 
provisions in the control of preserved and semipreserved canned goods, 
especially to detect anaerobic gasogenic or toxin-forming micro-
organisms with the greater assurance (Buttiaux, 1957; Mossel, 1956). A 
similar preincubation was proposed by Dony and Gèrard (Dony, 1968) 
for pharmaceutical products, but this appears pointless for pharmaceutical 
preparations for the following reasons: In food hygiene, the preincubation 
serves primarily to detect proteolytic, facultative, or strict anerobes, 
whereas, in general, pharmaceutical preparations do not provide optimal 
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conditions for anaerobic growth, and the materials used are usually a poor 
substance for growth of proteolytic organisms. 
It is of indisputable importance to know whether certain saprophytic or 
pathogenic organisms can grow in a preparation and whether an 
appropriate preservative is necessary. Such questions, however, must be 
answered in the development stage of the product by suitable spoilage or 
preservative tests (Bean, 1967). 
In determining the frequency of investigations, it is advantageous to 
distinguish between two groups of preparations. (I) Products in which 
only a relatively small number of micro-organisms can be tolerated or 
which are prone to contamination in such cases, an examination of each 
batch of the product is indicated. (II) Preparations with less rigid limits of 
contamination or which are less likely to be contaminated, such product 
can be controlled by periodic spot-checks. 
4.2. Characterization of isolates 
4.2.1. Characterization of bacteria 
4.2.1.1. Morphological characterizations 
 Colony characteristics on solid agar such as color, shape, 
consistency, emulsificability, odour, etc. were shown in table (13), in 
which it is clear that all isolates were circular, smooth, Entire, convex, 
have a size less than 1 mm and odourless. 
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4.2.1.2. Grams Reaction, Endo-spores and motility Results: 
 Table (14) shows all the bacterial isolates were Gram positive 
(except isolate 16 and 21), cocci, donot form an endospore, some were 
motile and the others were non-motile. 
Table (14) Gram`s Reaction, Endo-spores and motility Results 
No. of isolates Gram reaction Shape Endo spore Motility 
1 +ve  cocci - Non 
2 +ve  cocci - Non 
3 +ve  cocci - Non 
4 +ve  cocci - Non 
5 +ve  cocci - Mo 
6 +ve  cocci - No 
7 +ve  cocci - Non 
8 +ve  cocci - Mo 
9 +ve  cocci - Mo 
10 +ve  cocci - Non 
11 +ve  cocci - Non 
12 +ve  cocci - Non 
13 +ve  cocci - Non 
14 +ve  cocci - Mo 
15 +ve  cocci - Non 
16 -ve cocci - Mo 
17 +ve  cocci - Mo 
18 -ve cocci - Mo 
19 +ve  cocci - Non 
20 +ve  cocci - Mo 
21 -ve cocci - Non 
22 +ve  cocci - Mo 
23 +ve  cocci - Mo 
24 +ve  cocci - Mo 
25 +ve  cocci - Non 
26 +ve  cocci - Non 
27 +ve  cocci - Mo 
28 +ve  cocci - Non 
29 +ve  cocci - Non 
30 +ve  cocci - No 
31 +ve  cocci - Mo 
32 +ve  cocci - Non 
33 +ve  cocci - Mo 
34 +ve  cocci - Mo 
35 +ve  cocci - Non 
36 +ve  cocci - Mo 
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37 +ve  cocci - Non 
38 +ve  cocci - Non 
39 +ve  cocci - Non 
40 +ve  cocci - Mo 
41 +ve  cocci - Mo 
42 +ve  cocci - Mo 
43 +ve  cocci - Mo 
44 +ve  cocci - Non 
45 +ve  cocci - Non 
46 +ve  cocci - Mo 
47 +ve  cocci - Non 
48 +ve  cocci - Non 
49 +ve  cocci - Non 
50 +ve  cocci - Non 
+ve = Gram positive  -ve = Gram negative   non = non-motile mo = motile 
- = absent. 
4.2.1.3. Biochemical characterization: 
 Results of biochemical tests are shown in table (15) in which it is 
clear that all isolates tested were aerobic, indole negative, methyl red 
negative plate (1) (except isolate 22 and 41), V-P positive plate (2) except 
isolate (22 and 41), phosphatase positive plate (3), coagulase and DNAse 
negative palate (4) and plate (5) (except isolate 18, 43 and 44), and all of 
them are fermentative micro-organisms. All these biochemical tests are 
generally used in numerical taxonomic analysis of bacteria. 
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Plate (1) methyl red test, left a positive 
test. right a negative test 
Plate (5) Deoxyribonuclease (DNAse) 
test. Number 18 is positive test. 
Plate(6) Oxidase test (10 second) 30,32, a 
positive test. 31, a negative test. 
Plate (3) Phosphate test ,a positive test. 
Plate (8) Hydrogensulphide test. Left a 
positive test. Right a negative test. 
Plate(7) Motility Indol Urea(MIU) culture. 
Tube 1, motile urease negative.Tube 2, non 
motile urease negative.Tube 3, motile urease 
positive.Tube 4 nonmotile urease positive. 
  
Plate (4) Coagulase test, Upper, a 
positive test.. Centre, a positive 
control. Lower, a negative control. 
Plate (2) Voges-Proskauer test. Right, 
a positive test. Left, a negative test. 
Plate (9) Tube catalase test, 
Right a positive test. Left, a 
negative test.  
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        It has been found that the majority of isolates were Gram positive 
cocci that means it may be either staphylococcus or streptococcus, but the 
staphylococcus was rare and it was absent, by using treatment “use of 
musk, gloves, etc...”. The gram negative rods were not found, including 
members of Enterobacteriaceae. 
 The identification tests for genera and species may performed by 
using API 20NE kit to identify non-fastidious Gram-negative rods 
(Palmieri, 1988) not belonging to Enterobacteriaceae family, or BBL 
crystal enteric/non-fermenting ID kit that used for the identification of 
aerobic Gram-negative bacteria that belong to the family of 
Enterobacteriaceae as well as some of the more frequently isolated 
glucose fermenting and non-fermenting Gram-negative bacilli. 
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4.2.2. Characterization of fungi:  
 Table (16) shows the morphological and microscopical characters 
of isolated Fungi. 
  Table (16) Morphological and Microscopical Characters of Fungi 
No. of 
isolate 
Morphological character Microscopical character 
1 Cream Butrous, don’t produce a pigment 
in medium 
Spherical, reproduce vegetatively by budding 
2 White, Butrous, don’t produce a pigment 
in medium 
As above 
3 Green, have a mycelium and spores 
produce a pigment in the medium 
Aseptate hyphae of large diameter. The sporangiophores erect 
unbranched containing a large number of spherical spores, Rhizoid 
were absent 
4 As above Conidiophores are non-septate; arise from specialized, thick-walled 
hyphal cell. Each conidiophore ends in a terminal spherical swelling. 
The conidia unbranched chains, the chains arranged into radiate 
heads 
5 Brown, have a mycelium and spores, 
filamentous, don’t form a pigment in the 
medium. 
The conidiophore is branching and septate. Eight spored asci are 
produced 
6 Brown, have a mycelium and spores, 
produce pigment in the medium. 
The conidiophore is branching and septate. Eight spored asci are 
produced 
7 Black, have a mecillium and black spores. 
Don’t produce a pigment in the medium. 
Mycelium of non-septate hyphae of large diameter, develop rooted 
nod sporangiophores. Each sporanigiophore bears a terminal black 
spherical sporangium. The mycelium is thick and similar to cotton 
wool. 
8 As above Conidiophores are non-septate; arise from specialized, thick-walled 
hyphal cell. Each conidiophore ends in a terminal spherical swelling. 
The conidia unbranched chains, the chains arranged into radiate 
heads 
9 As above As above 
10 As above Mycelium of non-septate hyphae of large diameter, develop rooted 
nod sporangiophores. Each sporanigiophore bears a terminal black 
spherical sporangium. The mycelium is thick and similar to cotton 
wool. 
11 White, have a mycelium and black spores 
don’t produce a pigment in the medium. 
Conidiophores are non-septate; arise from specialized, thick-walled 
hyphal cell. Each conidiophore ends in a terminal spherical swelling. 
The conidia unbranched chains, the chains arranged into radiate 
heads. 
12 Green, have a mycelium and black spores 
don’t produce a pigment in the medium. 
Mycelium of septate hyphae, aseptate conidophre. The conidiophore 
is branched. 
13 black, have a mycelium and black spores 
don’t produce a pigment in the medium. 
Conidiophores are non-septate; arise from specialized, thick-walled 
hyphal cell. Each conidiophore ends in a terminal spherical swelling. 
The conidia unbranched chains, the chains arranged into radiate 
heads. 
 
In this study, it has been found that, all isolated micro-organisms 
were common laboratory contaminants and were not recovered from 
Wafrapharm products. The number of these micro-organisms decreased 
when a general cleaning using a disinfectant (Dettol) was performed. 
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 To confirm the identification genotypic methods were used. As 
stated earlier, genotyping identification methods have been successfully 
applied to the identification of fastidious organisms (e.g., Clamydia 
trachomatis and Neisseria gonorrhoeae), slow-growing organisms (e.g., 
fungal pathogens and Mycobacterium tuberculosis), rapid screening for 
pathogens (e.g., group A Streptococcus confirmatory testing), and 
unculturable organisms (e.g., the Whipple’s bacillus Tropheryma 
whippelii) (Whelen, 1996). Garaizar et al.,(1991) looked at the ability of 
ribotyping to identify Enterobacteriaceae isolates in comparison to a 
battery of conventional serological and biochemical assays and concluded 
that there was good agreement between identification by the genetic 
methods and the combination of conventional methods. Clabouts et al., 
performed a similar study with Clostridium difficile. Martin et al., (1996) 
with Escherichia coli, Nielsen et al., (2000) for Campylobacter jejuni, 
and Nadon et al.,(2001) for Listeria monocytogenes.  
 An excellent document that addresses both selection and validation 
of microbial identification methods is Cumitech 31: verification and 
validation of procedures in the clinical Microbiology Laboratory 
(Cumitech 31:, 1997). Another option is the AOAC International official 
Methods Program, which qualifies microbiological methods as official 
methods using interlaboratory collaborative studies (aoac.org). 
Additionally, USP has proposed a validation scheme (USP, 2003). 
However, the proposed USP chapter is unsatisfactory in several regards, 
not least of which is that it is an effort to address all aspects of the 
problem it has become so stilted and unwieldy that it is difficult to apply. 
Review of the medical literature has indicated that almost 90% of 
pharmaceutical products become contaminated during their use, 
especially at hospital environments. On the other hand, more than 50 % 
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of Paraenteral products become contaminated as a result of drug-addition 
and wrong manipulation of catheters and giving sets. Furthermore 
considerably high levels of microbial contamination were encountered in 
cosmetic products. 
Studies dealing with non-sterile pharmaceutical products indicated 
that aqueous preparations were generally more susceptible to microbial 
contamination than powder and solid dosage forms. In all these studies, 
great emphasis was made in the type of preparation contaminated and the 
route of administration. 
A total of 21 different brands of pharmaceutical products were 
selected from four major manufacturing firms in Sudan, to evaluate their 
aerobic bacterial contamination level. These products include 7 brands of 
tablet dosage forms, 6 brands of capsule dosage forms, 3 brands of liquid 
syrup and suspension, and 5 brands of dry suspension dosage forms; all 
of the tested items were found to be free from aerobic bacterial 
contaminants when the pour plate method was used. It was thus 
concluded that the pour plate method is the recommended viable count 
method stated by the official monographs. The purity of these products 
from contaminants may come from raw materials used in formulation and 
it comes from a good supplier, although the study found that some of the 
excipients used in formulation (Lactose monohydrate, Talc powder, and 
Corn starch) have a microbial growth less than 102 (non pathogenic 
micro-organisms), but it did not affect the preparations. Purity of the 
products may be resulting from use of good manufacturing practise rules 
(GMP) while the steps of preparations which include uses of gloves, 
masks, head covers, absence of wounds and shed skins, full clean 
clothing which completely shields the product from body surface, use of  
disinfectants before and after manufacturing process, use of clean 
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equipments, provide the manufacturing unit with an appropriate 
environmental condition (temperature, humidity, and air extraction), and 
use of partitions and separating rooms.  
From the primary microscopical examination for the environmental 
isolate, the bacterial isolates were classified into gram-positive cocci, and 
gram-negative cocci.  Accordingly, qualitative test of the detection for the 
presence of Staphyllococcus species within the gram positive coccal 
isolate, and Pseudomonas species, Escherichia coli and other 
Enterobacteriaceae within the gram-negative isolate were performed. 
From a total of 50 aerobic bacterial isolates, 47 (94%) were found to 
be gram-positive cocci, 3 (6%) were found to be gram-negative cocci, 
whereas 48 (96%) were identified as Coagulase-negative Staphylococcus. 
The fungal isolates were classified into septate or aseptate conidiophore. 
From a total of 13 isolates 2 (15%) were classified as a Yeasts, 6 (46%) 
were classified as Aspergillus species, 3 (23%) were classified as 
Rhizopous species, one isolate (7%) was classified as Penicillium species, 
and another one (7%) was classified as Byssochlamys species. 
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Conclusion 
 This Study offers support for implementation of an innovative 
technology in the analysis and control of materials used and produced by 
a pharmaceutical manufacturing operation. The methodology can be 
utilized to rapidly and reliably detect low level viable microbial isolates 
in pharmaceutical materials (Final Dosage Forms, Active Ingredients and 
Raw Materials).  
 The purpose of these studies was not to determine sterility of the 
product but to determine the minimal detectable number of organisms 
present. If the viable count is below the determinable level, the results are 
recorded as < 10 “less than 10”/g or < 0.1 “less than”/mL. where the 
interpretation of the results is to be based on the types of micro-organisms 
isolated and not the total count, details of the differential identification 
test should be given. In some water-insoluble products where only a very 
low level of contamination is acceptable, a quantitative method with 
direct inoculation into a liquid medium may be substituted for the 
described technique. 
 Microbial contamination can reduce the potency of a preparation, 
and affect the stability of the formulated product. Contamination can be 
overcome by sterilization, where appropriate. Sterilization will overcome 
the problems of microbial contamination but pyrogens, which have 
allergenic potential, may remain in the preparation. 
 Raw materials may be treated to reduce or eliminate microbial 
contamination by Gamma-irradiation, Ultra-violet radiation, Ethylene 
oxide and heat.   
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There is an urgent need for establishing certain minimum hygiene 
practices in preparation of pharmaceuticals in this environment. 
Otherwise, a lot of harm may be done to the health of those who 
patronize pharmaceuticals for medical care.  
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Appendix one 
Culture media 
The following media have been found satisfactory for the purposes for 
which they are prescribed in the test for microbial contamination and 
biochemical tests: 
Baird -Parkers Agar  
10.0 g Pancreatic digest of casein 
10.0 g Beef extract 
10.0 g Yeast extracts 
1.00 g Lithium chloride 
20.0 g Agar 
12.0 g Glycin 
10.0 g Sodium pyruvate 
950.0 mL Distilled water 
 Dissolve the ingredients by steaming .Adjust to pH 6.8 sterilize by 
autoclaving at 121° C for 15 minutes. Before pouring in the plates ,to 
each 90 mL of basal medium , melted and cool to 50 , add aseptically the 
following solution (all previously sterilized by filtration)in the amount 
given: 
6.5 mL 20 per cent w/v solution of glycine           
101 mL 1 per cent w/V solution of Potassium tellurite     
5.4 mL 20 per cent W/V solution of sodium pyruvate      
5.4 mL Egg- Yolk emulsion                                              
(Baird-Parker, 1962; Smith and Baird-Parker, 1964). 
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Brilliant green Agar 
10.0 g Peptone(meat and casein)   
3.00 g Yeast extract                       
5.00 g Sodium chloride                 
10.0 g Lactose monohydrate          
10.0 g Sucrose                                
20.0 g Agar                                    
80.0 mg Phenol red                           
12.5 mg Brilliant green                     
1000mL Distilled water                     
Heat to boiling for one minute. Adjust the pH so that after sterilization it 
is 6.7 to 7.1.immediatly before use, sterilize by heating in an autoclave at 
121° C for 15 minutes cool to 50° C and pour into sterile petri dishes. 
Casein soya Bean Digest Agar 
Pancreatic digest of casien     15.0 g 
Papaic digest of soya bean     5.00 g 
Sodium chloride                     5.00 g 
Agar                                       15.0 g 
Distilled water                        1000 mL 
Adjust the pH so that after sterilization it is 7.1 to 7.5. Sterilize by heating 
in an autoclave at 121° C for 15 minutes. 
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Cetrimide Agar 
Pancreatic digest of gelatin   20.0 g 
Magnesium chloride              1.4 g 
Potassium sulphate                10.0 g 
Cetrimide                               0.30 g 
Agar                                       13.6 g 
Glycerol                                 10.0 mL 
Distilled water                      1000 mL 
Heat to boiling for one minute with shaking. Adjust the pH so that after 
sterilization it is 7.0 to 7.4. Sterilize by heating in an autoclave at 121°C 
for 15 minutes. 
Christensen’s urea Agar 
Peptone                                                    1.0 g 
Sodium chloride                                      5.0 g 
Potassium dihydrogen orthophosphate   2.0 g 
D.Glucose                                                1.0 g 
Agar                                                         20.0 g 
Phenol red (0.2 per cent solution)           6 mL 
Distilled water                                         1000 mL 
Dissolve the ingredients in water. Adjust the final pH 6.8 to 7.0. Heat-
sterilize and cool to 50°C .Sufficient 20 per cent urea solution, previously 
sterilize by filtration, is then added to give final concentration 2 per cent 
(Christensen, 1964). 
 
 103
Deoxyribonucleic acid (DNAse) Agar 
Tryptose                              20.0 g 
Deoxyribonucleic acid        2.00g 
Sodium chloride                  5.00g 
Agar                                     12.0g 
Distilled water                     100 mL 
Dissolve the ingredients in water. Sterilize by autoclaving at 121°C for 15 
minutes. Adjust the final pH after sterilization 6.8 to 7.0. 
Deoxycholate Citrate Agar 
Heart infusion solids           10.0 g 
Proteose peptone                 10.0 g 
Lactose monohydrate          10.0 g 
Sodium citrate                     20.0 g 
Ferric ammonium citrate     2.0 g 
Deoxycholate                      5.0 g 
Neutral red                           20.0 mg 
Agar                                     13.5 g 
Distilled water                     1000 mL 
Adjust the pH so that after heating it is 7.1 to 7.5. Heat gently to boiling 
and boil for 1 minute, cool to 50°C and pour into Petri dishes; do not heat 
in an autoclave. 
Egg-Yolk emulsion 
Separate the yolk from the white of eggs and add four parts of distilled 
water to one part of egg yolk. Mix thoroughly and heat in a water-bath at 
45°C for two hours. Centrifuge to remove the precipitate. Decant the 
supernatant liquid, sterilize by filtration (Billing and Luckhurst, 1957). 
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Eosin Methylene Blue Agar 
Peptone                                                      10.0 g 
Lactose                                                      10.0 g 
Dipotassium hydrogen orthophosphate     0.7 g 
Monopotassium phosphate                       1.3 g 
Eosin Y                                                     0.4 g 
Agar                                                           12.0 g 
Distilled water                                           1000 mL 
Disperse the ingredients in water swirl to mix then sterilize by 
autoclaving at 121°C for 15 minutes. Adjust the pH after sterilization it is 
6.8 ±0.2 
Enterobacteriaceae Enrichment Broth –Mossel 
Pancreatic digest of gelatin                       10.0 g 
D-glucose monohydrate                            5.0 g 
Deoxyhydrate OX bile                              20.0 g 
Potassium dihydrogen orthophosphate     8.0 g 
Brilliant green                                            15.0 mg 
Distilled water                                           1000ml 
Adjust the pH so that after heating it is 7.0 to 7.4. Heat at 100°C for 30 
minutes and cool immediately. 
 105
Glucose Phosphate Peptone Broth 
D.glucose                                                   0.5 g 
Dipotassium hydrogen orthophosphate     0.5 g 
Peptone                                                      0.5 g 
Distilled water                                           100 mL 
 Sterilize by autoclaving at 121°C for 15 minutes. Adjust the pH after 
sterilization it is 7.5. 
Hugh and Leifson`s Medium 
Pepton                                                        0.2 g 
Sodium chloride                                         0.5 g 
Dipotassium hydrogen orthophosphate     30.0 mg 
Agar                                                           300 mg 
Bromothymol blue(1 per cent aqueous 
solution)                         
0.3 mL 
Distilled water                                           100 mL 
Mix the dry ingredients in the water then add the bromothymol blue 
indicator. Sterilize by autoclaving at 121°C for 15 minutes, adjust the pH 
to 7.1. After cool add 10 mL of a sterile10 per cent solution of the desired 
carbohydrate (previously sterilized by filtration). (Hug and Leifson 1953) 
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Lactose Monohydrate 
Pancreatic digest of gelatin     5.0 g 
Yeast extract                            2.5 g 
Sodium chloride                      2.5 g 
Lactose monohydrate              10.0 g 
Cysteine hydrochloride           0.3 g 
Distilled water                         1000 mL 
Dissolve; adjust to pH 7.0 to 7.2. Sterilize by autoclaving at 121°C for 15 
minutes. Before use, ad to the medium 62.5 mL of a 1.2 per cent W/V 
solution of metabisulphite and 62.5 mL of a 1 per cent W/V solution of 
ammonium (iii) citrate both solutions being freshly prepared and filtered 
through membrane (Pore size:0.45 mµ). 
MacConkey Agar 
Pancreatic digest of gelatin     17.0 g 
Peptone (meat and casien)      3.0 g 
Lactose monohydrate              10.0 g 
Sodium chloride                      5.0 g 
Bile salt                                   1.5 g 
Agar                                         13.5 g 
Neutral red                               30.0 mg 
Crystal violet                          1.0 mg 
Water                                       1000 mL 
Adjust the pH so that after sterilization it is 6.9 to 7.3. Boil for one minute 
with constant shaking then sterilize by autoclaving at 121°C for 15 
minutes. 
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Malt extract Agar 
Malt extract                           30.0 g 
Microbiological peptone       5.0 g 
Agar                                       15.0 g 
Distilled water                       1000 mL 
Sterilization by autoclaving at 121°C for 15 minutes. To inhibit the 
growth of bacteria the medium may be acidified to pH 3.5. This done by 
adding a sterile 10 per cent Lactic acid solution to the molten medium 
immediately before pouring in the plates. 
Nutrient Agar 
Peptone                                    10.0 g 
Meat extract lab-lemco            10.0 g 
Sodium chloride                     5.0 g 
Agar                                         15.0 g 
Distilled water                         1000 mL 
Sterilize by autoclaving at 121°C for 20 minutes. Adjust pH to 7.2. 
Peptone Water 
Tryptone                                  10.0 g 
Sodium chloride                      5.0 g 
Distilled water                         1000 mL 
Sterilize by autoclaving at 121°C for 15 minutes. Adjust to pH 7.2. 
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Pseudmonas Isolation Agar 
Pancreatic digest of gelatin     16.0 g 
Casein enzymic hdrolysate     10.0 g 
Potassium sulphate                  10.0 g 
Magnesium chloride 6.H2O    1.4 g 
Agar                                         11.0 g 
Distilled water                         1000 mL 
Suspend the ingredients in a water containing 5 mL glycerol sterilize by 
autoclaving at 121°C for 15 minutes . Cool to 50°C and aseptically add 
sterile rehydrate content of either Cetrinix Supplement or CFC 
Supplement. 
Sabouraud Glucose Agar (With antibiotic) 
Peptone (meat and casein)      10.0 g 
D-glucose monohydrate          40.0 g 
Agar                                         15.0 g 
Distilled water                         1000 mL 
Adjust the pH so that after sterilization it is 5.4 to 5.8. Sterilize by 
autoclaving at 121°C for 15 minutes. Immediately before use, add 0.1 
gram of Benzylpenicillin Sodium and 0.1 gram of Tetracycline or, 
alternatively, add 50 mg of chloramphenicol before sterilization. 
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Tetrathionate Bile Brilliant Green Broth 
Peptone                                    8.6 g 
Dehydrate OX bile                  8.0 g 
Sodium chloride                      6.4 g 
Calcium carbonate                   20.0 g 
Potassium tetrathionate           20.0 g 
Brilliant green                         70.0 mg 
Distilled water                        1000 mL 
Adjust the pH so that after heating it is 6.8 to 7.2. Heat just to boiling; 
don’t autoclave and reheat. 
Triple Sugar Iron Agar 
Beef extract                             3.0 g 
Peptone (Casien and Beef)      20.0 g 
Sodium chloride                      5.0 g 
Lactose monohydrate              10.0 g 
Ammonium iron (iii) itrate      0.3 g 
Sodium thiosulphate                0.3 g 
Phenol red                               25.0 mg 
Agar                                         12.0 g 
Distilled water                         1000 mL 
Adjust the pH so that after sterilization it is 7.2 to 7.6. Sterilize by 
autoclaving at 121°C for 15 minutes. 
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Tween Agar 
Peptone                                    10.0 g 
Calcium chloride hydrate        0.1 g 
Sodium chloride                      5.0 g 
Tween                                      10.0 mL 
Agar                                         15.0 g 
Distilled water                         1000 mL 
Sterilize by autoclaving at 121°C for 20 minutes. Adjust the pH to be 7.0 
to 7.4.   
Tween 80 (an oleic acid aster) is the tween most often used (Sierra, 1957). 
Violet Red Bile Agar 
Yeast extract                            3.0 g 
Pancreatic digest of gelatin     7.0 g 
Bile salt                                   1.5 g 
Lactose monohydrate              10.0 g 
Sodium chloride                      5.0 g 
D.glucose monohydrate          10.0 g 
Agar                                         15.0 g 
Neutral red                               30.0 mg 
Crystal violet                           2.0 mg 
Distilled water                         1000 mL 
Adjust the pH so that after sterilization it 7.2 to 7.6.heat to boiling but 
don’t heat in an autoclave. 
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Xylose, Lysine, Deoxycholate Agar 
D-xylose                                                    3.5 g 
L-lysine                                                     5.0 g 
Lactose monohydrate                               7.5 g 
Sucrose                                                      7.5 g 
Sodium chloride                                        5.0 g 
Yeast extract                                              3.0 g 
Phenol red                                                  80.0 mg 
Agar                                                           13.5 g 
Sodium deoxycholate                                6.8 g 
Ammonium iron (iii) citrate                      0.8 g 
Distilled water                                           1000 mL 
Adjust the pH so that after heating it is 7.2 to 7.6. Heat just to boiling. 
Cool to 50°C, don’t autoclave 
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Appendix Two 
Reagents &Stains 
Buffered Sodium Chloride-Peptone Solution PH 7.0 
Potassium dihydrogen orthophosphate     3.56 g 
Disodium hydrogen orthophosphate         7.23 g 
Sodium chloride                                         4.30 g 
Peptone                                                     1.00 g 
Distilled water                                           1000 mL 
0.1 to 1 per cent polysorbate 80 may be added, sterilize by autoclaving at 
121°C for 15 minutes.    
Crystal Violet Stain 
Crystal violet (gentian violet)                   1.0 g 
Potassium iodide                                       2.0 g 
Distilled water                                           300 mL 
 
Kovac`s Indole Reagent 
Pure amyl or isoamylalcohol                     150.0 mL 
Para-dimethylaminobenzaldehyde            10.0 g 
Concentrated pure hydrochloric acid        50.0 mL 
 Prepare reagent by dissolving the aldehyde in alcohol, then slowly 
adding the acid. Store in the refrigerator. 
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Lactophenol-Picric Acid 
Lactic acid                                             10.0 mL 
Phenol                                                    100.0 g 
Glycerol                                                 100.0 mL 
Picric acid (Saturated aqueous 
solution)                 
100.0 mL 
Dissolve the phenol in the picric acid solution without heating, and then 
add the lactic acid and glycerol. 
Malachite green 
Malachite green                                     0.1 g 
Distilled water                                       1000 mL 
(Fifield and haff, 1957) 
Mercuric chloride Solution 
Mercuric chloride                                 15.0 g 
Concentrated hydrochloric acid            20.0 mL 
Distilled water                                       100.0 mL 
(Smith et al., 1952) 
Methyl Red Solution 
Methyl red                                             0.1 g 
Ethanol 95 per cent                               300.0 mL 
Distilled water                                       200.0 mL 
Dissolve the methyl red in the ethanol, then make up to 500 mL with the 
distilled water. 
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Oxidase Reagent 
Tetramethyl-p-phenylenediamine Hydrochloride     1.0 g 
Distilled water                                                           100.0 mL 
This reagent may be kept in a dark bottle for up to two  
Weeks in a refrigerator. (Kovacs, 1956) 
Safranin 
Safranin                                                 0.1 g 
Distilled water                                       100.0 mL 
 
